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Background: Gonorrhoea is a common sexually transmitted infection that can cause pain and discomfort,
affect fertility in women and lead to epididymo-orchitis in men. Current treatment is with ceftriaxone, but
there is increasing evidence of antimicrobial resistance reducing its effectiveness. Gentamicin is a potential
alternative treatment requiring further evaluation.
Objectives: To assess the clinical effectiveness and cost-effectiveness of gentamicin as an alternative
treatment to ceftriaxone in the treatment of gonorrhoea.
Design: A multicentre, parallel-group, blinded, non-inferiority randomised controlled trial.
Setting: Fourteen sexual health clinics in England.
Participants: Adults aged 16–70 years with a diagnosis of uncomplicated, untreated genital, pharyngeal
or rectal gonorrhoea based on a positive Gram-stained smear on microscopy or a positive nucleic acid
amplification test (NAAT).
Randomisation and blinding: Participants were randomised using a secure web-based system, stratified
by clinic. Participants, investigators and research staff assessing participants were blinded to treatment
allocation.
Interventions: Allocation was to either 240 mg of gentamicin (intervention) or 500 mg of ceftriaxone
(standard treatment), both administered as a single intramuscular injection. All participants also received
1 g of oral azithromycin.
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Main outcome measure: The primary outcome measure was clearance of Neisseria gonorrhoeae at all
infected sites, confirmed by a negative Aptima Combo 2® (Hologic Inc., Marlborough, MA, USA) NAAT,
at 2 weeks post treatment.
Results: We randomised 720 participants, of whom 81% were men. There were 358 participants in the
gentamicin group and 362 in the ceftriaxone group; 292 (82%) and 306 (85%) participants, respectively,
were included in the primary analysis. Non-inferiority of gentamicin to ceftriaxone could not be demonstrated
[adjusted risk difference for microbiological clearance –6.4%, 95% confidence interval (CI) –10.4% to
–2.4%]. Clearance of genital infection was similar in the two groups, at 94% in the gentamicin group and
98% in the ceftriaxone group, but clearance of pharyngeal infection and rectal infection was lower in
the gentamicin group (80% vs. 96% and 90% vs. 98%, respectively). Reported pain at the injection site
was higher for gentamicin than for ceftriaxone. The side-effect profiles were comparable between the
groups. Only one serious adverse event was reported and this was deemed not to be related to the trial
medication. The economic analysis found that treatment with gentamicin is not cost neutral compared
with standard care, with average patient treatment costs higher for those allocated to gentamicin (£13.90,
95% CI £2.47 to £37.34) than to ceftriaxone (£6.72, 95% CI £1.36 to £17.84).
Limitations: Loss to follow-up was 17% but was similar in both treatment arms. Twelve per cent of
participants had a negative NAAT for gonorrhoea at their baseline visit but this was balanced between
treatment groups and unlikely to have biased the trial results.
Conclusions: The trial was unable to demonstrate non-inferiority of gentamicin compared with ceftriaxone
in the clearance of gonorrhoea at all infected sites. Clearance at pharyngeal and rectal sites was lower for
participants allocated to gentamicin than for those allocated to ceftriaxone, but was similar for genital sites
in both groups. Gentamicin was associated with more severe injection site pain. However, both gentamicin
and ceftriaxone appeared to be well tolerated.
Future work: Exploration of the genetic determinants of antibiotic resistance in N. gonorrhoeae will help
to identify accurate markers of decreased susceptibility. Greater understanding of the immune response to
infection can assist gonococcal vaccine development.
Trial registration: Current Controlled Trials ISRCTN51783227.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 20.
See the NIHR Journals Library website for further project information.
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Plain English summary
Gonorrhoea is a common infection, spread by having sex, that causes genital pain and discomfort. Inwomen it can lead to pelvic inflammation and infertility, and in men it can lead to swelling and pain
in the testicles. Currently, an antibiotic called ceftriaxone is used to treat gonorrhoea. However, there is
evidence that this is becoming less effective over time and it could stop curing patients with gonorrhoea
within the next few years.
In this study, we wanted to find out if another antibiotic called gentamicin is as good as ceftriaxone in the
treatment of gonorrhoea and whether or not gentamicin could be used to treat gonorrhoea if ceftriaxone
stops being effective.
We recruited 720 adults with gonorrhoea and randomly allocated them (by chance) to receive treatment
with an injection of either gentamicin (240 mg) or ceftriaxone (500 mg). They all also received a single
dose of azithromycin (1 g) taken by mouth.
Overall, 98% of participants given ceftriaxone had their gonorrhoea cured, compared with 91% of
participants given gentamicin, a difference of 7%. Therefore, it is likely that doctors will continue to use
ceftriaxone (plus azithromycin) as the preferred treatment. Gentamicin did have a cure rate of 94% for
genital gonorrhoea and so it might be useful when ceftriaxone is not available or appropriate to use. Cure
rates using gentamicin were lower than cure rates using ceftriaxone for gonorrhoea infecting the rectum
(90%) and throat (80%), so it may be less useful for patients with infections at these sites.
We also found that gentamicin is likely to cost the NHS more than ceftriaxone.
Gentamicin caused few side effects and seems to be as safe as ceftriaxone, which is reassuring.
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Scientific summary
Background
Gonorrhoea is a common sexually transmitted infection (STI) that causes genital pain and discomfort; in
women it can lead to pelvic inflammatory disease and infertility, and in men it can lead to epididymo-orchitis.
The current treatment is ceftriaxone plus azithromycin, but there is increasing evidence of cephalosporin
resistance, which is reducing this regimen’s effectiveness against gonorrhoea. A small but increasing number
of patients have already been found to have highly resistant strains of gonorrhoea, which have been
associated with treatment failure. The Gentamicin in the Treatment Of Gonorrhoea (G-TOG) trial aimed to
determine whether or not gentamicin is non-inferior to ceftriaxone in the treatment of gonorrhoea.
Objectives
Primary objective
The primary objective was to determine whether or not gentamicin is an acceptable alternative to
ceftriaxone for the treatment of gonorrhoea. This was addressed by determining whether or not the
microbiological clearance of Neisseria gonorrhoeae in participants allocated to gentamicin was non-inferior
to the clearance for participants allocated to ceftriaxone.
Secondary objectives
The secondary objectives were to determine:
l whether or not a single intramuscular (i.m.) dose of gentamicin is safe and well tolerated
l whether or not a single i.m. dose of gentamicin is cost-effective, from the perspective of the NHS,
when used to treat gonorrhoea
l the relationship between clinical effectiveness and the laboratory measurement of antibiotic effectiveness
[the minimum inhibitory concentration (MIC) required to inhibit growth of N. gonorrhoeae].
Methods
Trial design
Blinded, multicentre, non-inferiority, randomised trial comparing the clinical effectiveness, cost-effectiveness
and safety of gentamicin with those of ceftriaxone for the treatment of gonorrhoea.
Recruitment
Participants were recruited from outpatient sexual health clinics in England. Some clinics with a large
proportion of men who have sex with men attending were specifically selected to maximise the number of
participants with pharyngeal and rectal infections.
Eligibility
Adults aged 16–70 years were eligible for recruitment if they had received a positive diagnosis of
uncomplicated, untreated (i.e. they not received any antibiotic in the previous 28 days that could have
treated gonorrhoea, either partially or completely) genital, pharyngeal and/or rectal gonorrhoea in the
previous 4 weeks. The diagnosis was based on a positive Gram-stained smear on microscopy or a positive
nucleic acid amplification test (NAAT).
DOI: 10.3310/hta23200 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 20
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ross et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
The exclusion criteria were having known concurrent bacterial STI (apart from chlamydia); having known
bacterial vaginosis and/or Trichomonas vaginalis infection; having known contraindications or an allergy to
gentamicin, ceftriaxone, azithromycin or lidocaine; having a current clinical diagnosis of complicated
gonorrhoea infection, for example pelvic inflammatory disease or epididymo-orchitis; weighing < 40 kg;
and receiving or having received ceftriaxone, gentamicin or azithromycin within the preceding 28 days.
Pregnant and/or breastfeeding women were also excluded. Participants were eligible to participate in the
trial only once.
Interventions
Both treatments were administered from routine clinic stock as a single i.m. injection.
For the ceftriaxone group, 500 mg of ceftriaxone in powder formulation was dissolved in 1% lidocaine and
administered as a single 2-ml i.m. injection.
For the gentamicin group, 240 mg (3 × 80 mg in 2-ml vials) of gentamicin was administered as a single
6-ml i.m. injection.
In addition, all participants received a single oral dose of 1 g of azithromycin, which is currently given in
the UK as standard treatment alongside ceftriaxone.
Outcomes
Primary outcome
The primary outcome was clearance of N. gonorrhoeae, confirmed by a negative Aptima Combo 2®
(Hologic Inc., Marlborough, MA, USA) NAAT, 2 weeks post treatment (as recommended by the British
Association for Sexual Health and HIV) at all infected sites.
Secondary outcomes
The secondary outcomes were:
l clinical resolution of symptoms
l frequency of nausea/vomiting, hearing loss, dizziness and rash
l frequency of any other adverse events (AEs) reported by participants
l tolerability of injection as assessed by the participant on a visual analogue scale (VAS)
l comparative cost-effectiveness.
The relationship between clearance of N. gonorrhoeae and in vitro measurement of antibiotic MIC to
inhibit N. gonorrhoeae growth was also assessed.
Effectiveness, tolerability and safety were assessed at a follow-up visit 2 weeks post treatment.
Sample size
Based on 96% clearance for the ceftriaxone regimen, a total sample size of 646 participants (323 in each
group) was required for analysis to detect non-inferiority with a lower 95% confidence interval (CI) for the
absolute risk difference of 5%, 90% power and a one-sided significance level of 0.025. To allow for a loss
to follow-up of 10%, the trial aimed to recruit a total of 720 participants.
Randomisation and blinding
Randomisation was in a 1 : 1 ratio, stratified by recruiting centre. A computer-generated pseudorandom
code, using permuted blocks of randomly varying size, was created by the Nottingham Clinical Trials Unit in
accordance with their standard operating procedure and held on a secure server. Participants, investigators
and research staff assessing the participants were blinded to treatment allocation. The sequence of
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treatment allocations remained concealed until the database was locked at the end of the trial, when it was
revealed to data analysts.
Statistical methods
Demographic and clinical measures were compared between the randomised arms at baseline using
appropriate descriptive statistics for continuous and categorical variables.
The primary approach to between-group comparative analyses was by intention to treat without imputation
of missing outcome data. Sensitivity analyses were conducted to investigate the impact of missing primary
outcome data using simple and multiple imputation. The primary outcome comparing gentamicin with
ceftriaxone was the difference in the proportion of participants clear of infection at 2 weeks’ follow-up,
along with the 95% CI. Gentamicin was regarded as non-inferior if the lower 95% CI for the risk difference
in confirmed clearance was ≥ –5 percentage points (i.e. nearer zero). This was evaluated using a generalised
estimating equation for binary outcomes, adjusted by recruiting centre as a random effect, with robust
standard errors.
The secondary outcomes were similarly analysed using appropriate regression models dependent on data
type, adjusted for clinic site and baseline value of the outcome variable, if collected. To explore treatment
efficacy by site of infection, for each of the three infection sites, we separately estimated clearance by
treatment arm along with 95% CIs.
The relationship between clinical effectiveness and MIC was examined visually.
Safety and tolerability analyses were descriptive. Frequency counts and percentages of the prespecified
main categories of AEs were presented by treatment arm.
Health economics
The economic analysis compared the costs associated with the current standard treatment, ceftriaxone,
with those of the proposed alternative treatment, gentamicin, in the treatment of gonorrhoea. Given that
the primary objective of the trial was to determine non-inferiority of gentamicin compared with ceftriaxone,
the economic analysis focused on establishing whether or not the use of gentamicin rather than ceftriaxone
was cost neutral in the treatment of gonorrhoea. This involved the collection and analysis of data on costs
and NHS resource use to determine whether or not there were any differences between the two treatments.
These data were collected via trial processes and a patient questionnaire at the 2-week follow-up.
Results
The trial randomised 720 participants: 358 to receive gentamicin and 362 to receive ceftriaxone. Eighty-one
per cent of participants were male, 69% were white and 13% had an human immunodeficiency virus
infection. Fourteen participants did not receive their allocated medication, of whom 10 were in the gentamicin
group and four were in the ceftriaxone group. Primary outcome data were available for 306 participants
(85%) randomised to receive ceftriaxone and 292 participants (82%) randomised to receive gentamicin.
In total, 299 (98%) of the participants allocated to ceftriaxone had clearance at 2 weeks, compared with
276 (91%) of the participants allocated to gentamicin, an adjusted risk difference of –6.4% (95% CI –10.4%
to –2.4%). Clearance at genital sites was 98% and 94%, at pharyngeal sites was 96% and 80% and at
rectal sites was 98% and 90% in ceftriaxone- and gentamicin-allocated participants, respectively. Nausea
was experienced by 12% and 14% of participants, vomiting by 1% and 4%, reduction in hearing by 2% and
1%, dizziness/unsteadiness by 7% and 7% and skin rash by 2% and 4% in the ceftriaxone and gentamicin
groups, respectively. The majority of participants reported injection site pain (98% and 99% in the ceftriaxone
and gentamicin treatment groups, respectively), with the mean pain score, measured by a VAS, greater in the
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gentamicin group (21 vs. 36). The median time to resolution of injection pain was 1 hour for ceftriaxone and
1.5 hours for gentamicin. Fifteen per cent of participants allocated to ceftriaxone and 13% allocated to
gentamicin reported at least one AE. The majority of AEs were mild (45/54 in the ceftriaxone group and 35/43
in the gentamicin group). One serious AE (grade 4 dizziness) was reported and it was not considered to be
related to the trial treatment.
The economic analysis found that, from a health-care perspective, treatment with gentamicin was not cost
neutral compared with standard care. Average patient treatment costs were found to be higher for the
gentamicin trial arm (£13.90, 95% CI £2.47 to £37.34) than for the ceftriaxone arm (£6.72, 95% CI £1.36
to £17.84). However, within the economic evaluation, it was not possible to consider the potential issues
associated with antimicrobial resistance (AMR) in gonorrhoea.
Conclusions
Implications for health care
The G-TOG trial was unable to demonstrate the non-inferiority of gentamicin compared with ceftriaxone in
microbiological clearance of gonorrhoea at 2 weeks’ follow-up. Therefore, it is likely that clinicians will
want to continue to use ceftriaxone (plus azithromycin) as their preferred first-line therapy. Secondary
analyses suggested that gentamicin was potentially non-inferior to ceftriaxone with respect to clearance of
genital gonorrhoea (94% vs. 98%), so it is possible that gentamicin could be used for patients who are
allergic or intolerant to ceftriaxone or who have a gonorrhoea infection that is resistant to ceftriaxone.
However, further work would be needed to confirm non-inferiority. The lower cure rates for rectal (90%)
and pharyngeal infection (80%) make gentamicin a less attractive treatment option, but antibiotics are
generally less effective at these sites and gentamicin may still be useful as a second- or third-line therapy.
A repeat test for gonorrhoea to ensure microbiological cure would be advisable following gentamicin
therapy.
Azithromycin is currently used as part of dual therapy for gonorrhoea to ‘protect’ ceftriaxone by
theoretically reducing the risk of resistance developing and by providing microbiological cover in case
cephalosporin resistance develops. The observation in the G-TOG trial that a 1-g dose of azithromycin,
even in combination with gentamicin, has a significant failure rate raises concerns about the effectiveness
of 1 g of azithromycin in the treatment of gonorrhoea and, therefore, whether or not its use as a
component of dual therapy will reduce the risk of future AMR developing.
A single dose of 240 mg of gentamicin was found to cause few AEs and had a safety profile comparable
to that of ceftriaxone, which provides reassurance regarding its use in clinical practice.
The economic analysis showed that, currently, gentamicin is likely to be more costly than ceftriaxone in the
treatment of gonorrhoea. However, it was not possible to take into account the costs associated with AMR
for gonorrhoea.
Recommendations for research
Further exploration is needed into why gentamicin treatment is not effective in some patients and whether
or not its efficacy can be predicted. Whole-genome sequencing may allow the identification of specific
genetic markers of N. gonorrhoeae resistance and provide insights into the mechanisms and predictors of
resistance.
The development of a preventative or therapeutic gonococcal vaccine is a priority because of increasing
resistance and limited future antibiotic options. Greater understanding of the immune response to
infection is required to facilitate this.
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A 1-g dose of azithromycin combined with gentamicin was associated with a relatively high failure rate,
with the lowest clearance rates seen in pharyngeal infection. This suggests that azithromycin may not be
the optimal antibiotic to use as part of dual therapy designed to slow the spread of resistance. Further
studies are required to evaluate alternative ‘second agents’.
Further research is needed to examine the costs associated with AMR in gonorrhoea. In addition, there is a
need for the development of appropriate methods for economic evaluations of interventions to address
AMR in gonorrhoea and other disease areas.
Trial registration
This trial is registered as ISRCTN51783227.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Gonorrhoea is the second most common bacterial sexually transmitted infection (STI) in the UK, with
36,244 infections reported in 2016.1 A disproportionate burden of infection is seen in young adults (36% of
infections occur in those aged < 25 years) and minority ethnic groups (23% of infections occur in non-white
people). The highest rates of infection are in large urban areas and are concentrated in core groups that
include men who have sex with men (MSM), black people and minority ethnic groups, and those reporting
multiple sexual partners. Over the past few years, there has been a significant rise in rectal gonorrhoea in
MSM, thought to reflect an increase in detection using sensitive nucleic acid amplification tests (NAATs)2
and an increase in unsafe sexual behaviour.1,3
Gonorrhoea leads to local inflammation, causing genital pain and discomfort; the localised immune activation
associated with infection also facilitates the acquisition and transmission of human immunodeficiency virus
(HIV).4 In women, infection can spread to the fallopian tubes and ovaries, causing pelvic inflammatory disease,
with resultant tubal scarring, infertility and chronic pelvic pain and an increased risk of ectopic pregnancy. In
men, gonorrhoea can lead to epididymo-orchitis and, in MSM, gonococcal proctitis can lead to abscess and
fistula formation. Pharyngeal infection, although usually asymptomatic, is an important reservoir of onward
transmission in both women and MSM. It is also harder to treat with antibiotics and can persist even when
antimicrobial susceptibility testing suggests that it should be susceptible.5 It is, therefore, important to know
whether or not treatment is effective for infection at all anatomical sites.
Antibiotic treatment and resistance
Neisseria gonorrhoeae readily develops resistance to antibiotic regimens. Globally, there are now high
levels of resistance against penicillins, sulphonamides, tetracyclines and quinolones, all of which are no
longer recommended for routine use.6 A real possibility of multidrug-resistant gonorrhoea and the lack of
alternative treatment options has been highlighted.7 Guidance from the British Association for Sexual Health
and HIV (BASHH) recommends treating gonorrhoea with ceftriaxone (given with adjunctive azithromycin)
and this currently cures > 95% of patients.8 Recent surveillance data show a reduction in sensitivity to
ceftriaxone with an upwards drift in the minimum inhibitory concentration (MIC); that is, the proportion of
cases that remain highly sensitive to ceftriaxone has decreased over time.3 Sporadic treatment failure of
cephalosporins has been reported from a number of countries9–14 and a patient who failed dual therapy with
ceftriaxone plus azithromycin has recently been documented in the UK.15 The same reduction in antibiotic
susceptibility was followed by widespread treatment failure within a few years for other antimicrobials
(penicillin, tetracyclines and quinolones) used to treat gonorrhoea. An outbreak of azithromycin-resistant
gonorrhoea has been reported in England since November 2014, further highlighting the need to identify
other effective treatment regimens.16 Despite this recent outbreak, azithromycin resistance remains
uncommon in England and, overall, levels of azithromycin resistance have probably not increased over the
past 3 years since the outbreak was first identified, although a change in laboratory procedures in 2015
makes direct comparisons over time difficult. Current national and international treatment guidelines
continue to recommend dual antibiotic therapy, including azithromycin, for the treatment of gonorrhoea.
Alternative treatments
The options for treating gonorrhoea are limited if cephalosporins become ineffective. With the exception
of gentamicin, alternative agents have not been fully assessed in vivo [such as ertapenem (Invanz;® Merck,
Sharpe & Dohme, Kenilworth, NJ, USA), solithromycin, gepotidicin],17–20 are reserved for specific infections
(e.g. rifampicin for tuberculosis)21 or have the potential to rapidly develop resistance (e.g. spectinomycin).22
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Two systematic reviews on gentamicin monotherapy23,24 reported cure rates for gentamicin of 62–98%
in patients with gonorrhoea, but available studies were generally small and of low quality. No adverse
events (AEs) were reported in these studies. A more recent non-comparative prospective trial25 evaluated
single-dose gentamicin combined with 2 g of oral azithromycin with a reported cure rate of 100% in mostly
genital infections. Limited data are available on the efficacy of gentamicin when treating gonorrhoea in the
pharynx or rectum, although antibiotics are sometimes less effective at these sites.
As the susceptibility of N. gonorrhoeae to currently recommended antibiotics decreases and multidrug-
resistant strains become more common, it is important to demonstrate the efficacy and safety of
alternative treatment regimens in patients with gonorrhoea. Gentamicin is a relatively cheap and widely
available antibiotic. Despite an apparent dose-related association with renal and vestibulocochlear toxicity,
a single one-off dose appears to be well tolerated.26 In vitro antimicrobial susceptibility data support the
use of gentamicin, but there is a need for clinical trial data to assess its efficacy and safety, particularly in
pharyngeal and rectal infections.27
Research question
Our hypothesis was that gentamicin was not clinically worse than ceftriaxone in the treatment of gonorrhoea.
This randomised controlled trial (RCT) tested this hypothesis by comparing the microbiological clearance of
N. gonorrhoeae following treatment with either gentamicin or ceftriaxone.
Objectives
Primary objective
The primary objective was to determine whether or not gentamicin is an acceptable alternative to
ceftriaxone in the treatment of gonorrhoea. This was addressed by determining whether or not the rate of
microbiological clearance of N. gonorrhoeae in participants treated with gentamicin was non-inferior to
the rate of clearance in participants treated with ceftriaxone.
Secondary objectives
The secondary objectives were to determine:
l whether or not a single intramuscular (i.m.) dose of gentamicin is safe and well tolerated
l whether or not a single i.m. dose of gentamicin is cost-effective for the NHS in comparison to
ceftriaxone for the treatment of gonorrhoea
l the relationship between clinical effectiveness and the laboratory measurement of antibiotic
effectiveness (the MIC required to inhibit growth of N. gonorrhoeae).
INTRODUCTION
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Chapter 2 Methods
Study design
The Gentamicin in the Treatment Of Gonorrhoea (G-TOG) trial was a blinded, two-arm, multicentre,
non-inferiority, randomised trial comparing the clinical effectiveness and safety of gentamicin with that
of ceftriaxone in the treatment of gonorrhoea.
Participants were randomised to receive a single i.m. injection of either gentamicin or ceftriaxone. In
addition, all participants received 1 g of oral azithromycin as standard treatment. The primary outcome was
clearance of N. gonorrhoeae at all infected sites, indicated by a negative NAAT, 2 weeks post treatment.
The secondary outcomes included clearance of N. gonorrhoeae at genital, pharyngeal and rectal sites;
clinical resolution of symptoms; frequency of AEs; tolerability of therapy; the relationship between clinical
effectiveness and antibiotic MIC for N. gonorrhoeae; and cost-effectiveness.
Trial setting and participants
Recruiting centres
The trial was conducted in 14 sexual health clinics in England. Seven sites were originally planned to meet
the recruitment target and a further seven sites were added during the trial. Sites were opened between
September 2014 and February 2016, with participants being recruited from October 2014 to November
2016.
Identification of participants
Patients with a provisional (microscopy identification of Gram-negative cocci on a Gram stain of genital
secretions) or confirmed (indicated by a positive NAAT) diagnosis of gonorrhoea were screened for the trial
and approached by a member of the site research team to determine whether or not they were interested
in participating. They were provided with a patient information sheet (PIS) and a verbal explanation of the
trial and were given the opportunity to ask any questions that they might have. In addition, trial posters
were on display in relevant areas of the clinic. These helped to introduce the trial and, if patients were
interested, they could ask clinic staff for additional details. All participants gave written informed consent.
To avoid delaying treatment for a transmissible infection with serious sequelae, patients with either a
provisional (on microscopy) or confirmed (on NAAT) diagnosis of untreated gonorrhoea were invited
to participate and provide written consent at the same clinic visit.
Eligibility criteria
Patients were eligible for inclusion if they were aged 16–70 years and had a positive diagnosis in the
previous 4 weeks of uncomplicated, untreated (i.e. they had not received any antibiotic in the previous
28 days that could have treated gonorrhoea, either partially or completely) genital, pharyngeal and/or rectal
gonorrhoea. The exclusion criteria were having known concurrent STI(s) (excluding chlamydia); bacterial
vaginosis and/or Trichomonas vaginalis infection; having contraindications or an allergy to gentamicin,
ceftriaxone, azithromycin or lidocaine; being pregnant or breastfeeding; having complicated gonorrhoeal
infection, for example pelvic inflammatory disease or epididymo-orchitis; weighing < 40 kg; and having
used ceftriaxone, gentamicin or azithromycin in the preceding 28 days.
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Assessment of feasibility
At 9 months after the start of recruitment, accrual was reviewed by the Trial Steering Committee (TSC)
to determine whether or not the following feasibility criteria had been met for progression:
l Recruitment at 80% of target. If this was not achieved, the Trial Management Group (TMG) would
implement effective and realistic strategies to increase recruitment and retention for the study to proceed.
l Percentage of completed follow-ups of > 50%.
If the study did proceed, an additional assessment of recruitment would be carried out.
On 22 June 2015, the trial received approval for progression, having met the feasibility criteria. At 9 months,
88% of target recruitment had been achieved, with follow-up of 74%. Recruitment was assessed regularly
at monthly TMG meetings and at further TSC meetings.
Trial procedures
Baseline visit
Demographic information and details of a participant’s sexual history and symptoms were collected during
the baseline visit. Symptomatic and asymptomatic individuals were eligible for inclusion in the trial. For
symptomatic participants, the baseline visit usually took place on the same day as diagnosis, which was
based on the microscopy appearances of Gram-stained genital discharge. Asymptomatic participants were
recalled to the clinic for treatment after a positive test result for gonorrhoea had been received; once they
had given consent to participate in the trial, this second visit (the first following diagnosis) was considered
as the baseline visit.
Each participant had swabs taken for NAAT and culture testing to determine the site(s) of infection. A urine
sample could be taken in place of a NAAT urethral sample for men. A full sampling profile was required,
taking account of a participant’s sex and sexual orientation, to reflect potential sites of exposure. This
allowed the efficacy of treatment to be assessed at each infected site. When swabs or urine specimens
were not part of routine clinical care or had not been taken already during the baseline clinic visit
(e.g. symptomatic participants who had only swabs taken for routine care on the same day prior to
consent), additional swabs were taken to complete the full sampling profile, as defined in Table 1.
TABLE 1 Sampling schedule for trial participants28
Sex/reported sexual orientation
Sample
Genital Pharyngeal Rectal
Females ✓a ✓c ✓c
Heterosexual men ✓b Not required Not required
MSM ✓b ✓c ✓c
a Culture sample from cervix plus NAAT sample from vagina or cervix.
b Culture sample from urethra plus NAAT sample from urine or urethra.
c Culture sample plus NAAT sample.
Reproduced from Brittain et al.28 © The Author(s). 2016 Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
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All specimens collected were sent to local site laboratories for the identification of N. gonorrhoeae and
results were reported back to the clinics in the usual manner. The results from the baseline visit informed
subsequent testing of previously infected sites at the follow-up visit.
A number of licensed NAATs are available to detect N. gonorrhoeae, including the Hologic Aptima
Combo 2® (AC2) assay (Hologic, Inc., Marlborough, MA, USA). In centres where the AC2 assay was not
used locally for testing, an additional set of swabs (or urine) was taken for the AC2 assay to be performed
at Public Health England (PHE). These results were not reported back to the clinic but were reported in
batches to the Nottingham Clinical Trials Unit (NCTU). The AC2 assay was, therefore, considered as the
reference standard for the trial and the AC2 NAAT result was used as the primary outcome measure.
The management of participants was based only on the results of local testing.
Additional blood samples were taken for future measurement of the pre-treatment immune response to
gonococcal infection and for measurement of creatinine level.
Follow-up
Participants were asked to return to the clinic 2 weeks post treatment (which was also 2 weeks post
randomisation) for a follow-up visit. Participants were reminded of their appointment using the individual
clinics’ existing recall procedures, such as Short Message Service (SMS) and telephone reminders. During
the follow-up visit, swabs (or urine) from previously infected sites were taken for NAAT and culture testing
to assess the clearance of N. gonorrhoeae. A blood sample was taken to measure the post-treatment
immune response and creatinine level. Each participant remained in the trial until this follow-up visit was
completed. Participants were considered lost to follow-up if they had not returned for their follow-up
appointment within 60 days of the baseline visit; this time point was chosen pragmatically to balance
flexibility over when participants could return to the clinic against the potential increased risk of reinfection
over a more prolonged time period. The recruitment flow diagram is shown in Figure 1.
If follow-up test results at 2 weeks post treatment showed that a participant had gonorrhoea, he or she
was offered further investigation and treatment in accordance with local clinic guidelines. This treatment
was not considered to be part of the trial.
Randomisation
After providing consent, and after confirmation of eligibility, participants were registered in the trial using a
secure web-based registration and randomisation system. Participants were randomised to receive either
gentamicin or ceftriaxone by a member of the research team. Staff who performed randomisation had no
role in administering trial treatments and remained blinded to the treatment allocation, thereby minimising
the risk of selection bias through prediction of the allocation sequence.
Randomisation was based on a computer-generated pseudorandom code using permuted blocks of
randomly varying size. The code was created by NCTU in accordance with standard operating procedures
and held on a secure server. Randomisation was carried out in a 1 : 1 ratio, stratified by recruiting centre.
The web-based system generated a blinded prescription for G-TOG trial treatment, which required
signature by the prescribing doctor. Site staff recorded only ‘G-TOG trial drug’ in the participants’ medical
notes. The signed prescription was then passed to an injecting nurse who determined the actual treatment
that a participant was randomised to and then administered the injection. The injecting nurse was the only
member of the research team who was unblinded to treatment allocation.
Interventions
Participants were randomised to receive either 240 mg of gentamicin (intervention) or 500 mg of ceftriaxone
(current standard treatment). Both treatments were administered from routine clinic stock as a single i.m.
injection. Any European Union-licensed brands of gentamicin and ceftriaxone were permitted to be used.
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Patients attending a NHS sexual health outpatient clinic
with suspected gonorrhoea
Symptomatic Asymptomatic
Visit 1: baseline
Sample taken for immediate
microscopy and gonorrhoea
NAAT from sites at risk of
infection (as routine)
Positive patients provided
with trial information
Consent and baseline data
collection
Additional swabs for NAAT
and culture testing to 
complete a full screen 
for gonorrhoea
Blood taken for creatinine 
and immune testing
Additional swabs for AC2
NAAT if applicable
Additional swabs for NAAT
and culture testing to 
complete a full screen 
for gonorrhoea 
Blood taken for creatinine 
and immune testing
Additional swabs for AC2
NAAT if applicable
Randomised
Administer treatment: EITHER
i.m. gentamicin OR i.m. ceftriaxone,
plus oral dose of azithromycin
Participant completes VAS pain score
Visit 2: follow-up (2 weeks)
Data collected on sexual history, 
symptoms, side effects, health-care 
usage and AEs
Swabs taken for NAAT and culture 
testing from previously infected sites
Additional swabs for AC2 NAAT if 
applicable
Blood taken for creatinine and 
immune testing
Pre-trial visit
Sample taken for gonorrhoea
NAAT from sites at risk of
infection (as routine)
Visit 1: baseline
Positive patients provided
with trial information
Consent and baseline data
collection
Positive Gram-stained smear
on microscopy
Positive NAAT
Interested in participating in
trial – refer to research nurse
Interested in participating in
trial – refer to research nurse
FIGURE 1 The G-TOG trial flow diagram. VAS, visual analogue scale. Reproduced from Brittain et al.28 © The
Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated.
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The 240 mg of gentamicin was made up from three 2-ml (80-mg) vials, in accordance with the Summary
of Product Characteristics (SmPC), and administered as a single 6-ml i.m. injection. For the ceftriaxone
arm, 500 mg in a powder formulation was dissolved in 1% lidocaine, in accordance with the SmPC, and
administered as a single 2-ml i.m. injection. In addition, all participants received a single oral dose of 1 g
of azithromycin, which is currently given as standard treatment alongside ceftriaxone.
In previous trials, a 240-mg dose of gentamicin was most commonly used and the use of different doses has
not demonstrated a significant dose–response effect across studies.23,24 In vitro antimicrobial susceptibility
testing also suggests that isolates remain sensitive to gentamicin.27,29 The dose of ceftriaxone was chosen to
be consistent with current UK gonorrhoea treatment guidelines.30
Blinding
Nurses administering trial treatments were required to know each participant’s allocation as they prepared
the drug for injection. Details of the nurses administering treatment at each centre were obtained during
the trial set-up stage and access to the online randomisation system and treatment allocation was granted
depending on the delegated role. All other staff at the recruiting centres remained blinded to treatment
allocation.
Preparation and administration of trial treatments was undertaken in a separate area, away from the
blinded research team and participants. In addition, nurses administering treatments were given guidance
to provide standardised information to participants at the time of injection, which was the same regardless
of treatment allocation, to prevent inadvertent unblinding. This two-step approach maintained blinding for
members of the research team who were subsequently involved in the assessment of participants.
To ensure that assessment of outcome was not influenced by knowledge of the allocated treatment,
nurses administering trial treatments were not permitted any role in the collection of outcome data.
End of the trial
Participants left the trial when they completed their 2-week follow-up visit.
Failure to receive the allocated treatment and withdrawal from follow-up were reported and reasons
for withdrawal (if given) were documented. If a participant did not receive his or her allocated treatment
but agreed to remain in the trial, outcome data collection continued in accordance with the protocol.28
Participants were informed at the start of the trial that data collected up to the point of withdrawal would
be retained and used in the final analysis.
Outcome measures
Primary outcome
The primary outcome measure was clearance of N. gonorrhoeae at all infected sites, confirmed by a
negative NAAT, at 2 weeks post treatment (as recommended by BASHH).
The NAAT is an automated laboratory test and, therefore, not subject to bias through knowledge of
treatment allocation. Different licensed NAAT assays for the diagnosis of gonorrhoea are available from
different manufacturers [e.g. AC2 NAAT; Becton, Dickinson and Company (BD) NAAT (BD, Franklin Lakes,
NJ, USA); Cobas® NAAT (Roche Diagnostics, Basel, Switzerland)]. Sexual health clinics participating in the
G-TOG trial used either the AC2 NAAT or the BD NAAT; therefore, in order to ensure consistency and
standardisation in diagnostic and follow-up tests, additional samples were taken from participants
recruited at centres where the AC2 NAAT method was not used by the local laboratory. Testing of these
additional samples by AC2 NAAT was performed by PHE. The results from the AC2 NAAT were used to
assess clearance for the primary end point.
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Secondary outcomes
The secondary outcomes were:
l clinical resolution of symptoms
l frequency of nausea/vomiting, hearing loss, dizziness and rash
l frequency of any other AEs reported by participants
l tolerability of injection as assessed by participants on a visual analogue scale (VAS)
l cost-effectiveness.
The relationship between clearance of N. gonorrhoeae and in vitro measurement of antibiotic MIC to
inhibit N. gonorrhoeae growth was also assessed.
Effectiveness, tolerability and safety were assessed at the follow-up visit 2 weeks post treatment.
Clinical resolution of symptoms
Resolution of each individual clinical symptom was defined as absence of the symptom at 2 weeks post
treatment in those participants with symptoms present at baseline.
Frequency of nausea/vomiting, hearing loss, dizziness and rash
Information recorded for each symptom comprised whether or not the participant had experienced the
symptom, the severity of that symptom, the time to the start of the symptom from injection with trial
medication, the duration of that symptom and whether or not it had resolved.
Frequency of any other adverse events
An AE is defined as any untoward medical occurrence in a participant administered a medicinal product
that does not necessarily have a causal relationship with the treatment. Participants were asked if they had
any AEs in addition to the potential side effects collected. The information collected comprised a verbatim
description of the event, the severity of the event and the duration of the event. These AEs were then
coded using MedDRA (Medical Dictionary for Regulatory Activities; version 17.1).31 All AEs were assessed
for seriousness. A serious adverse event (SAE) is defined as any untoward medical occurrence that results
in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in
persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
Additional safety information
In addition to the collection of data on side effects and AEs, participants had a blood sample taken to
measure their creatinine levels at baseline and at 2 weeks post treatment. These levels were used to
calculate the estimated glomerular filtration rate (eGFR).
Tolerability of the intramuscular injection
Tolerability of the injection was measured immediately after the injection and then at the 2-week clinic
visit. It was measured using a 100-mm VAS that asked ‘How severe was the pain of the injection when
at its worst?’. A score of 0 denoted no pain and a score of 100 denoted the worst imaginable pain.
Measurement of antibiotic minimum inhibitory concentrations
Minimum inhibitory concentrations were established at PHE using Etests® (BioMérieux UK Ltd, Basingstoke,
UK) for gentamicin (0.016–256 mg/l), ceftriaxone (0.002–32 mg/l) and azithromycin (0.016–256 mg/l) on
gonococcal agar with Vitox [gonococcal agar base (BD Difco™; BD, Wokingham, UK) and 1% Vitox (Oxoid
Ltd, Basingstoke, UK)]. Before the Etest, the gonococcal isolates were confirmed to be N. gonorrhoeae by
Gram stain, oxidase test and matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF; Bruker,
Billerica, MA, USA).
METHODS
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Research governance
The trial was conducted in accordance with the recommendations adopted by the 18th World Medical
Association General Assembly, Helsinki, 196432 and later revisions; the NHS Research Governance
Framework for Health and Social Care (2nd edition);33 and the principles of the International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use – Good
Clinical Practice guidelines.34
The National Research Ethics Service Oxford C – South Central Research Ethics Committee (reference:
14/SC/1030) gave ethics approval for the trial for NHS participants (reference: 155423).
The final protocol, approved on 17 June 2015, was version 2.0. There were a number of administrative
and procedural changes made to the protocol during the trial, which are outlined in Appendix 1.
Protocol deviations
A protocol deviation was defined as an unanticipated or unintentional divergence or departure from the
expected conduct of the trial, inconsistent with the protocol, consent document or other trial procedures.
Protocol deviations were recorded by site staff. Protocol violations were defined as deviations that affected
eligibility or outcome measures, as assessed by the TMG.
Trial oversight
A number of oversight groups monitored ongoing progress for the duration of the trial and also
contributed to interpretation of findings. Roles and responsibilities were defined including the use of
charters for the independent TSC and Data Monitoring Committee (DMC).
Trial Management Group
The TMG, which was responsible for the day-to-day running of the trial, comprised the chief investigator,
members of NCTU and other core members of the trial team, for example health economists.
Trial Steering Committee
The TSC, which met approximately every 6 months, included an independent chairperson and five
independent members and was responsible for overseeing the conduct of the trial. Independent members
were professionals in reproductive and sexual health as well as clinical epidemiology. The TSC also had two
independent patient and public involvement (PPI) representatives and the chief investigator and trial
manager. The TSC monitored trial progress, specifically, advising on recruitment and follow-up strategies
and ensuring adherence to the trial protocol. The trial funder and sponsor were invited to attend meetings
as observers.
Data Monitoring Committee
The DMC, which met approximately every 6 months, was an independent group with expertise in
statistics, primary care and sexual health. They had access, in confidence, to unblinded data by allocated
group. The role of the DMC was to safeguard the interests of trial participants, with particular reference to
the safety of the intervention; to monitor the overall progress and conduct of the trial; and to assist and
advise the TSC and the investigators. The DMC reported to the TSC and, therefore, met shortly before TSC
meetings and reported to the TSC on trial safety and recommendations for continuation or stopping of
the trial.
Risk assessment and safety monitoring
A risk assessment was conducted as part of protocol development; there was regular monitoring
throughout the trial for new risks. The main risks to the trial were loss to follow-up in a young, sometimes
transient, population and poor data collection owing to the very short time frame for trial participation of
just 2 weeks. However, recruitment sites were well supported by NCTU in obtaining high-quality data and
regular central monitoring checks were performed to identify any issues with data collection that could be
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followed up at individual site level. Data on AEs and SAEs were collected during the trial. As agreed by the
sponsor, the Research Ethics Committee, the DMC and the TSC, the DMC was provided with a list of all
AEs and SAEs, including any deaths, for review at each meeting.
Patient and public involvement
Twenty-four patients from three sexual health clinics (Birmingham, London and Manchester) commented on
the trial design in June and July 2012. A further 25 patients in Birmingham reviewed a PIS for the trial in
April 2013. Input was requested on the trial concept and design, whether or not patients with gonorrhoea
would be likely to consent to take part in the proposed trial design and the clarity of the patient information
provided. Patients’ main concerns following the initial consultation exercise were around the amount of
time that participation would involve and whether or not the therapies being offered were safe. In response,
the trial procedures were reviewed to optimise patient flow and the draft PIS was revised to expand the
information on safety and AEs. Based on the revised patient information, 24 out of 25 patients in the
second consultation exercise would have been happy to consider participation in the trial.
Two members of the public joined the TSC and provided input into the design and management of the
trial. Specifically, they were invited to comment on all aspects of the trial design and conduct and to
contribute to the design and review of documentation given to trial participants to ensure understanding
and acceptability. This greatly benefited the research by helping to ensure that our material was acceptable
and comprehensible, thus increasing our response rate and reducing the number of missing data. The
public members of the TSC commented on the best way of sharing trial findings with the public and
contributed as part of the research team to the interpretation of the trial findings. At each stage of the
trial, the G-TOG trial team aimed to provide the PPI representatives with clear information in lay terms to
allow them to participate in discussing the research, but not to bias their perspective towards that of the
researchers/clinicians.
A lay summary of the trial findings, informed by our public members, will also be disseminated to
participants who consented to receive the results.
Payments to participants
Participants were not paid to participate in the trial; however, at the end of their follow-up visit they were
provided with a £15 voucher to compensate for the additional time associated with taking part in the trial.
Statistical methods
Sample size
Based on a clearance rate of 96% for the ceftriaxone regimen, consistent with previous trials, it was
estimated that a total sample size of 646 participants for analysis (323 in each group) would achieve 90%
power at the 2.5% one-sided significance level to detect non-inferiority with a lower 95% confidence
interval (CI) for the absolute risk difference of 5%. It was planned to randomise a total of 720 participants
to allow for a loss to follow-up rate of ≤ 10%.
Analysis plan
A statistical analysis plan (SAP) was finalised before database lock and release of treatment codes to the
statistician. All summaries and statistical analyses were conducted using Stata® version 13.1 (StataCorp LP,
College Station, TX, USA).
Analysis data sets
Intention-to-treat data set
This data set comprised participants as randomised, regardless of adherence to their allocated group and
without imputation for missing data [intention-to-treat (ITT) principle].
METHODS
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Safety data set
The safety data set comprised participants as per the treatment that they actually received.
No specific per-protocol analysis data set was required as several sensitivity analyses were planned to
investigate the robustness of the primary outcome.
Data derivations
Clearance of Neisseria gonorrhoeae
Clearance of N. gonorrhoeae at all sites was derived from a post-treatment negative AC2 NAAT at the
sites that were positive pre treatment. All sites that were positive pre treatment for an individual
participant had to be negative post treatment for gonorrhoea to be considered cleared.
Sensitivity analyses were performed when the AC2 NAAT data were not available and when other data
were missing.
Resolution of clinical symptoms
Resolution of each individual clinical symptom was defined as absence of the symptom at 2 weeks post
treatment in those participants who had symptoms present at baseline. Each symptom was summarised
individually.
Changes in creatinine and estimated glomerular filtration rate
The absolute change in creatinine level from baseline to 2 weeks post treatment for each participant was
calculated. In addition, the following variables were derived:
l Whether or not each participant had a clinically important change between baseline and 2 weeks post
treatment. A clinically important change was defined by the study team as an increase or decrease of
> 30% from baseline.
l Whether or not the creatinine level at 2 weeks post treatment exceeded the upper normal limit value.
These upper limits were determined by the local laboratory that analysed the samples.
l eGFR was calculated using the following formula (Chronic Kidney Disease Epidemiology Collaboration).35
The change in eGFR was then calculated by subtracting the eGFR at 2 weeks post treatment from the
eGFR at baseline, where min is minimum, max is maximum, Scr is serum creatinine (mg/dl), κ = 0.7
(female) or 0.9 (male) and α = –0.329 (female) or –0.411 (male):
eGFR = 141 × min(Scr /κ, 1)α × max(Scr /κ,1)−1:209 × 0:993Age × 1:018 ½if female × 1:159 ½if black. (1)
Minimum inhibitory concentration data
Data were summarised on a per-participant basis. For overall summaries, when a participant had more
than one value for MIC (e.g. when samples had been taken from more than one site), the largest value
was used. When data were summarised by clearance, the data derived for the primary end point
(i.e. cleared of infection at all sites as determined by the AC2 NAAT) were used.
Missing data
The primary analysis was performed on the ITT data set without imputation of missing data for clearance
of N. gonorrhoeae at 2 weeks. When the baseline tests did not show any sites positive for N. gonorrhoeae
or the baseline test results were missing, the results of positive pre-trial tests were used.
Sensitivity analyses of the primary outcome were performed on the ITT data set to check the robustness of
the conclusions to missing outcome data. The pattern of missing data was explored overall and in each of
the two treatment groups. When clearance at 2 weeks post treatment using the AC2 NAAT was missing,
but there were data for the BD NAAT, the result of the BD NAAT was used for a sensitivity analysis.
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Three imputation methods were applied when data for the clearance of N. gonorrhoeae (both the AC2
and the BD NAAT) at 2 weeks post treatment were missing:
1. multiple imputation using chained equations
2. assume that all missing data show clearance of N. gonorrhoeae
3. assume that all missing data show non-clearance of N. gonorrhoeae.
Table 2 outlines possible scenarios when a value for the primary outcome could be derived. Scenarios not
included in this table resulted in missing primary outcome data.
Analysis of the primary outcome
The analysis of the primary outcome was modified from that specified in the protocol. This amendment
was made before the database was locked and the treatment codes revealed.
The initial planned method of analysis was to use a general linear model for binary outcome adjusted by
clinic site, with the primary efficacy parameter comparing gentamicin with ceftriaxone being the risk
difference in the proportion of participants clear of infection at 2 weeks’ follow-up, along with the 95% CI.
However, during the trial, additional centres were introduced, some of which could recruit only small
numbers of participants. This meant that there was a chance that some centres would have no participants
who had ‘failed’ treatment, making the inclusion of centre as a fixed effect inappropriate. Therefore, the
primary approach to the between-group comparative analyses was modified to use generalised estimating
equations (GEEs) for binary outcomes adjusted by recruiting centre as a random effect with robust standard
errors. The GEE model used an identity link function to enable estimation of adjusted risk difference. The
primary efficacy parameter comparing gentamicin with ceftriaxone was the risk difference in the proportion
of participants clear of infection at all sites, determined by the AC2 NAAT at the 2-week follow-up, along
with the 95% CI. Gentamicin was to be regarded as non-inferior if the lower 95% confidence limit for the
risk difference (gentamicin group vs. ceftriaxone group) in confirmed clearance was ≥ –5 percentage points
(i.e. closer to zero).
Sensitivity analyses for the primary outcome
In addition to the sensitivity analyses outlined in Missing data, we also investigated the treatment efficacy
by performing the following sensitivity analyses:
l exclude participants who did not have any positive samples at baseline
l exclude participants who did not receive the allocated treatment
l exclude participants who did not have full baseline samples taken, that is, females and MSM should
have had genital, rectal and pharyngeal samples taken and heterosexual men should have had genital
samples taken.
TABLE 2 Scenarios of primary outcome availability
Visit
Primary outcome
available?
Baseline Follow-up
Tests Results Tests Results
All required samples taken ≥ 1 positive All positives retested + or – Yes
No positivea All pre-trial positives retested + or – Yes
Not all required samples taken ≥ 1 positive All positives (from pre trial
and baseline) retested
+ or – Yes
No positive All pre-trial positives retested + or – Yes
Any positive follow-up AC2 NAAT Yes
a Based on baseline NAAT test and Gram stain test.
METHODS
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It was planned that there would be an additional analysis further adjusting for baseline variables with
a marked imbalance between treatment groups identified after the treatment codes were revealed.
However, there were no marked imbalances considered likely to influence the results of the trial; therefore,
this additional analysis was not appropriate.
Secondary outcomes
Clearance of Neisseria gonorrhoeae by infection site
Participants may have had infection at multiple sites on entry to the trial, with up to seven different
combinations of one, two and three sites possible. For each of the three infection sites, we separately
estimated clearance by treatment arm along with 95% CIs, rather than formally fitting an interaction term
for different combinations of infection site in the regression model. Any suggestion of a differential effect
according to infected site would require confirmation in future research.
Clinical resolution of symptoms
The evaluation of clinical resolution was performed using GEEs for binary outcomes adjusted by recruiting
centre as a random effect. The efficacy parameter comparing gentamicin with ceftriaxone was the risk
difference in the proportion of participants clear of clinical symptoms at the 2-week follow up, along with
the 95% CI. These symptoms were genital discharge, dysuria, sore throat, anorectal pain, rectal bleeding,
rectal discharge, tenesmus, constipation, intermenstrual bleeding and post-coital bleeding. The assessment
of all symptoms at baseline was recorded for all participants, irrespective of their site(s) of infection.
Creatinine level at 2 weeks
The creatinine-related binary outcomes [number of participants having a clinically important change and
number of participants exceeding the upper limit of normal (using the local laboratory ranges) at 2 weeks
post treatment] and change in eGFR were summarised using basic descriptive statistics. Shift plots were
presented to identify extreme values.
Minimal inhibitory concentration for trial medications
The MIC distribution data were plotted and summarised overall and, separately, by infection site for each
antimicrobial. It was expected that some data values would be below or above quantifiable limits; therefore,
plots of the MIC value distribution for each medication (gentamicin, ceftriaxone and azithromycin) were
produced. For overall summaries, when a participant had more than one MIC (e.g. when they had samples
taken from more than one site), the largest of these MICs was used.
Concomitant medications
Additional antibiotics and other concomitant medications taken during the trial were listed by treatment
group.
Side effects/adverse events
Descriptive summaries of side effects and AEs by treatment group were provided:
l Number and percentage of participants who reported each of the following – nausea, vomiting,
hearing loss, dizziness and rash. The total numbers of times that these side effects were reported are
also summarised.
l Severity and time in hours or days from injection to onset of each of the following – nausea, vomiting,
hearing loss, dizziness and rash.
l Visual analogue scale pain score immediately following injection and recollection of injection pain at
the 2-week follow-up visit.
l All non-serious AEs and all SAEs were coded using MedDRA.31 The number and proportion of
participants who experienced any AE or SAE were summarised.
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Chapter 3 Results
Recruitment
Recruitment commenced in October 2014 and continued until November 2016 when the recruitment
target was met (Figure 2).
Participant flow is shown in Figure 3.
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FIGURE 2 Monthly actual recruitment.
Patients with N. gonorrhoeae
who were approached
(n = 1762)
Randomised
(n = 720)
Allocated to ceftriaxone
(n = 362)
• Received allocated medication, n = 358
• Did not receive allocated medication, n = 4
Allocated to gentamicin
(n = 358)
• Received allocated medication, n = 348
• Did not receive allocated medication, n = 10
Primary outcome not available
[n = 56 (15%)]
• Withdrew consent, n = 1
• Lost to follow-up, n = 36
• Incorrect sampling at follow-up, n = 16
• Other, n = 3
Primary outcome not available
[n = 66 (18%)]
• Withdrew consent, n = 0
• Lost to follow-up, n = 47
• Incorrect sampling at follow-up, n = 10
• Other, n = 9
Included in primary analysis
[n = 306 (85%)]
Included in primary analysis
[n = 292 (82%)]
FIGURE 3 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
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Between 7 October 2014 and 14 November 2016, 1762 patients were approached, of whom, 1042 (59%)
were not randomised: 331 were not eligible, 174 declined to participate, 169 felt that participation in the
trial would take too much time and 368 were not randomised because of ‘other’ reasons. The main ‘other’
reasons included having a needle phobia, having taken antibiotics in the preceding 4 weeks, not being
able to attend follow-up and appropriate staff not being available.
In total, 720 patients were randomised from 14 sexual health clinics in England: 362 (50%) were
randomised to receive ceftriaxone and 358 (50%) were randomised to receive gentamicin (Table 3).
All participants were randomised on the day of their clinic visit.
Baseline characteristics
The baseline characteristics of the 720 participants are provided in Table 4. The population comprised 585
(81%) men, 134 (19%) women and one participant classified as ‘other’. The mean age was 30 years with
a range of 16–70 years. Sixty-nine per cent of participants were white and 13% were HIV positive.
Most (n = 633, 88%) participants had a positive diagnosis of N. gonorrhoeae at their baseline attendance
by either NAAT or Gram stain (Table 5). There was a slight imbalance between treatment groups in terms
of a positive diagnosis using Gram stain (38% in the ceftriaxone group vs. 46% in the gentamicin group),
but there was balance between groups in those diagnosed using NAAT and overall. Slightly more
participants had infection at the genital site in the gentamicin group than in the ceftriaxone group (61%
vs. 52%). Similar percentages of participants in each group had pharyngeal and rectal infections. Fifty-one
per cent of participants were infected at only one site, 26% at two sites and 10% at three sites. Overall,
baseline characteristics between the two treatment groups were well balanced.
TABLE 3 Trial recruitment by intervention arm and participating site
Site
Treatment group (n)
Total (N)Ceftriaxone Gentamicin
Whittall Street Clinic, Birmingham 87 86 173
Barts Sexual Health Centre 35 34 69
Burrell Street Clinic, Guy’s and St Thomas Hospital 45 47 92
Leeds Sexual Health 50 50 100
Manchester Centre for Sexual Health 14 16 30
Sheffield 46 44 90
Southampton Department of Sexual Health 14 13 27
Chelsea and Westminster 19 19 38
Brighton 8 8 16
Coventry 18 17 35
Royal Free 3 2 5
Royal Berkshire 7 6 13
St Mary’s 12 13 25
John Hunter Clinic 4 3 7
All sites 362 358 720
RESULTS
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TABLE 4 Baseline characteristics of participants
Characteristic
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
Age at randomisation (years)
Mean (SD) 30.2 (10.1) 30.4 (9.9) 30.3 (10)
Median (25th percentile, 75th percentile) 27.5 (22.6, 34.9) 28.2 (22.9, 35.1) 27.9 (22.7, 35.0)
Minimum, maximum 16.1, 70.2 16.5, 68.4 16.1, 70.2
Sex, n (%)
Male 293 (81) 292 (82) 585 (81)
Female 69 (19) 65 (18) 134 (19)
Other 0 1 (< 0.5) 1 (< 0.5)
Ethnicity, n (%)
White 241 (67) 255 (71) 496 (69)
Black 53 (15) 48 (13) 101 (14)
Asian 26 (7) 18 (5) 44 (6)
Mixed 27 (7) 26 (7) 53 (7)
Other 15 (4) 11 (3) 26 (4)
Country of birth, n (%)
UK 258 (71) 253 (71) 511 (71)
Other 104 (29) 105 (29) 209 (29)
If other, region
Europe (non-UK) 51 (14) 56 (16) 107 (15)
North America 8 (2) 5 (1) 13 (2)
Asia Pacific 18 (5) 14 (4) 32 (4)
Latin America 7 (2) 11 (3) 18 (3)
Middle East 2 (1) 5 (1) 7 (1)
Africa 18 (5) 14 (4) 32 (4)
Creatinine level (µmol/l)
Mean (SD) 78.6 (15.4) 78.3 (15.8) 78.5 (15.6)
Median (25th percentile, 75th percentile) 78 (69, 88) 77 (67.5, 86.0) 77 (68, 87)
Minimum, maximum 42, 137 26, 154 26, 154
N 343 332 675
Medical history, n (%)
Diabetes mellitus 3 (1) 1 (< 0.5) 4 (1)
Otitis media 9 (2) 7 (2) 16 (2)
Renal disease 3 (1) 4 (1) 7 (1)
Liver disease 8 (2) 5 (1) 13 (2)
Immunodeficiency 34 (9) 24 (7) 58 (8)
Any known drug allergies 17 (5) 25 (7) 42 (6)
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The treatment groups appeared to be balanced with respect to participants’ history of STIs [41% of
participants had had at least one previous diagnosis of gonorrhoea, 34% of participants had previously
had chlamydia, 14% had had syphilis and 3% had had pelvic inflammatory disease (women only)]
(Table 6). The number and type of sexual partners were similar in the two treatment groups, as were
other details of their sexual history (Tables 7 and 8).
The results of the clinical examination and symptom assessment at baseline were similar between the
treatment groups. Slightly fewer participants in the ceftriaxone group than in the gentamicin group had
evidence of genital discharge on clinical examination (45% vs. 54%; Table 9). Similarly, at the baseline
symptom assessment, 42% of participants in the ceftriaxone group and 50% in the gentamicin group
reported the presence of genital discharge (Table 10). Few participants had hearing impairment at
baseline [8 out of 362 (2%) in the ceftriaxone group and 11 out of 358 (3%) in the gentamicin group].
All impairments were mild with the exception of two participants in the ceftriaxone group who reported severe
hearing impairment and one participant in the gentamicin group who reported moderate hearing impairment.
TABLE 4 Baseline characteristics of participants (continued )
Characteristic
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
HIV infection status,a n (%)
Negative 299 (83) 307 (86) 606 (84)
Positive 53 (15) 43 (12) 96 (13)
Unknown 10 (3) 8 (2) 18 (3)
SD, standard deviation.
a Based on previous test or new test at baseline.
TABLE 5 Description of N. gonorrhoeae infection and diagnosis at baseline
Baseline diagnosis and infection
Treatment group, n (%)
Total (N= 720),
n (%)Ceftriaxone (N= 362) Gentamicin (N= 358)
Participants with a positive diagnosis at
baseline attendancea
317 (87) 316 (88) 633 (88)
Participants with infection at each sitea
Genital 190 (52) 219 (61) 409 (57)
Pharyngeal 128 (35) 128 (36) 256 (36)
Rectal 159 (44) 147 (41) 306 (43)
Number of sites infecteda
1 189 (52) 180 (50) 369 (51)
2 96 (27) 94 (26) 190 (26)
3 32 (9) 42 (12) 74 (10)
Positive diagnosis of N. gonorrhoeae using
Gram stainb
139 (38) 166 (46) 305 (42)
Positive diagnosis of N. gonorrhoeae using
AC2 NAATc
308 (85) 309 (86) 617 (86)
a Positive tests using either AC2 NAAT or Gram stain.
b Total of 224 and 239 participants had Gram stain test at baseline for ceftriaxone and gentamicin group, respectively.
c Samples from clinics using BD NAAT were also tested using AC2 NAAT at PHE. No results using BD NAAT are presented.
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TABLE 6 Participant STI history at baseline
STI history
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
Previously had a positive diagnosis for gonorrhoea, n (%)
No 205 (57) 214 (60) 419 (58)
Yes 152 (42) 142 (40) 294 (41)
Not known 5 (1) 2 (1) 7 (1)
Number of previous episodes experienced
Median (25th percentile, 75th percentile) 1 (1, 2) 1 (1, 3) 1 (1, 2)
Minimum, maximum 1, 25 1, 6 1, 25
n 152 142 294
Previously had a positive diagnosis for chlamydia, n (%)
No 235 (65) 228 (64) 463 (64)
Yes 121 (33) 127 (35) 248 (34)
Not known 6 (2) 3 (1) 9 (1)
Number of episodes experienced
Median (25th percentile, 75th percentile) 1 (1, 2) 1 (1, 2) 1 (1, 2)
Minimum, maximum 1, 20 1, 7 1, 20
n 121 127 248
Previously had a positive diagnosis for syphilis, n (%)
No 311 (86) 302 (84) 613 (85)
Yes 48 (13) 53 (15) 101 (14)
Not known 3 (1) 3 (1) 6 (1)
Number of episodes experienced
Median (25th percentile, 75th percentile) 1 (1, 1) 1 (1, 1) 1 (1, 1)
Minimum, maximum 1, 2 1, 4 1, 4
n 48 53 101
Previously had a positive diagnosis for pelvic inflammatory disease (female only), n (%)
No 67 (97) 64 (97) 131 (97)
Yes 2 (3) 2 (3) 4 (3)
Unknown 0 0 0
Number of episodes experienced
Median (25th percentile, 75th percentile) 1.5 (1, 12) 2 (1, 3) 1.5 (1, 2.5)
Minimum, maximum 1, 2 1, 3 1, 3
n 2 2 4
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TABLE 6 Participant STI history at baseline (continued )
STI history
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
Previous HIV test, n (%)
No 69 (19) 66 (18) 135 (19)
Yes 289 (80) 286 (80) 575 (80)
Not known 4 (1) 6 (2) 10 (1)
If yes
Positive 52 (14) 42 (12) 94 (13)
Negative 237 (65) 244 (68) 481 (67)
TABLE 7 Sexual history at baseline (males)
Baseline sexual history
Treatment group
Total (N= 585)Ceftriaxone (N= 293) Gentamicin (N= 292)
Number of partners in the previous 3 months
Median (25th percentile, 75th percentile) 3 (2, 6) 3 (2, 5) 3 (2, 5)
Minimum, maximum 0, 50 0, 99 0, 99
Number of partners in the previous 12 months
Median (25th percentile, 75th percentile) 7 (3, 20) 6 (3, 18) 6 (3, 20)
Minimum, maximum 1, 192 1, 500 1, 500
Previous history of same-sex partner (ever), n (%)
No 77 (26) 75 (26) 152 (26)
Yes 216 (74) 216 (74) 432 (74)
Not known 0 1 (< 0.5) 1 (< 0.5)
Previous history of receptive anal sexual intercourse (ever), n (%)
No 93 (32) 98 (34) 191 (33)
Yes 200 (68) 193 (66) 393 (67)
Not known 0 1 (< 0.5) 1 (< 0.5)
Previous history of receptive oral sexual intercourse (ever), n (%)
No 55 (19) 47 (16) 102 (17)
Yes 238 (81) 243 (83) 481 (82)
Not known 0 2 (1) 2 (< 0.5)
Previous history of partner born outside the UK (ever), n (%)
No 105 (36) 89 (30) 194 (33)
Yes 181 (62) 196 (67) 377 (64)
Not known 7 (2) 7 (2) 14 (2)
In the previous 3 months, for approximately what proportion of sexual contacts were condoms used?
Median (25th percentile, 75th percentile) 50 (0, 93) 50 (5, 95) 50 (0, 95)
Minimum, maximum 0, 100 0, 100 0, 100
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TABLE 7 Sexual history at baseline (males) (continued )
Baseline sexual history
Treatment group
Total (N= 585)Ceftriaxone (N= 293) Gentamicin (N= 292)
Latest partner
Sex, n (%)
Male 212 (72) 211 (72) 423 (72)
Female 81 (28) 80 (27) 161 (28)
Missing 0 1 (< 0.5) 1 (< 0.5)
Time (days) since last sexual intercourse
Median (25th percentile, 75th percentile) 10 (6, 21) 10 (5, 18) 10 (6, 21)
Minimum, maximum 1, 196 1, 210 1, 210
Duration of last relationship, n (%)
One-off 128 (44) 131 (45) 286 (40)
Occasional 56 (19) 60 (21) 134 (19)
Regular 95 (32) 89 (30) 251 (35)
Previous regular 14 (5) 9 (3) 45 (6)
Not known 0 3 (1) 3 (1)
Type of sexual contacta, n (%)
Genital–genital 152 (52) 144 (49) 296 (51)
Anal–genital 119 (41) 122 (42) 241 (41)
Genital–anal 143 (49) 149 (51) 292 (50)
Oral–genital 214 (73) 211 (72) 425 (73)
Genital–oral 228 (78) 239 (82) 467 (80)
Oral–anal 85 (29) 87 (30) 172 (29)
Anal–oral 87 (30) 74 (25) 161 (28)
Digital–anal 81 (28) 86 (29) 167 (29)
Anal–digital 72 (25) 68 (23) 140 (24)
Use of condoms, n (%)
No 159 (54) 142 (49) 301 (51)
Yes, partially 49 (17) 52 (18) 101 (17)
Yes, consistently, including for oral sex 7 (2) 8 (3) 15 (3)
Yes, consistently, but not for oral sex 78 (27) 89 (30) 167 (29)
Missing 0 1 (< 0.5) 1 (< 0.5)
Partner known to have gonorrhoea, n (%)
No 257 (88) 250 (86) 507 (87)
Yes 36 (12) 41 (14) 77 (13)
Not known 0 1 (< 0.5) 1 (< 0.5)
a Not mutually exclusive.
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TABLE 8 Sexual history at baseline (females)
Baseline sexual history
Treatment group
Total (N= 134)Ceftriaxone (N= 69) Gentamicin (N= 65)
Number of partners in the previous 3 months
Median (25th percentile, 75th percentile) 1 (1, 2) 1 (1, 2) 1 (1, 2)
Minimum, maximum 0, 120 0, 100 0, 120
Number of partners in the previous 12 months
Median (25th percentile, 75th percentile) 3 (1, 4) 2 (1, 4) 2 (1, 4)
Minimum, maximum 1, 120 1, 300 1, 300
Previous history of same-sex partner (ever), n (%)
No 65 (94) 62 (95) 127 (95)
Yes 4 (6) 2 (3) 6 (4)
Not known 0 1 (2) 1 (1)
Previous history of receptive anal sexual intercourse (ever), n (%)
No 48 (70) 45 (69) 93 (69)
Yes 21 (30) 19 (29) 40 (30)
Not known 0 1 (2) 1 (1)
Previous history of receptive oral sexual intercourse (ever), n (%)
No 15 (22) 17 (26) 32 (24)
Yes 54 (78) 47 (72) 101 (75)
Not known 0 1 (2) 1 (1)
Previous history of partner born outside the UK (ever), n (%)
No 42 (61) 46 (71) 88 (66)
Yes 24 (35) 17 (26) 41 (31)
Not known 3 (4) 2 (3) 5 (4)
In the previous 3 months, for approximately what proportion of sexual contacts were condoms used?
Median (25th percentile, 75th percentile) 0 (0, 50) 0 (0, 50) 0 (0, 50)
Minimum, maximum 0, 100 0, 100 0, 100
Latest partner
Sex of latest sexual partner, n (%)
Male 69 (100) 63 (97) 132 (98)
Female 0 1 (2) 1 (1)
Missing 0 1 (2) 1 (1)
Time (days) since last sexual intercourse
Median (25th percentile, 75th percentile) 14 (7, 21) 14 (7, 28) 14 (7, 28)
Minimum, maximum 1, 112 1, 112 1, 112
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TABLE 8 Sexual history at baseline (females) (continued )
Baseline sexual history
Treatment group
Total (N= 134)Ceftriaxone (N= 69) Gentamicin (N= 65)
Duration of last relationship, n (%)
One-off 15 (22) 12 (18) 27 (20)
Occasional 8 (12) 10 (15) 18 (13)
Regular 33 (48) 33 (51) 66 (49)
Previous regular 13 (19) 9 (14) 22 (16)
Not known 0 1 (2) 1 (1)
Type of sexual contact,a n (%)
Genital–genital 67 (97) 63 (97) 130 (97)
Anal–genital 7 (10) 5 (8) 12 (9)
Genital–anal 0 2 (3) 2 (1)
Oral–genital 48 (70) 37 (57) 85 (63)
Genital–oral 43 (62) 36 (55) 79 (59)
Oral–anal 3 (4) 1 (2) 4 (3)
Anal–oral 4 (6) 2 (3) 6 (4)
Digital–anal 4 (6) 3 (5) 7 (5)
Anal–digital 3 (4) 6 (9) 9 (7)
Use of condoms, n (%)
No 49 (71) 46 (71) 95 (71)
Yes, partially 15 (22) 10 (15) 25 (19)
Yes, consistently, including for oral sex 0 2 (3) 2 (1)
Yes, consistently, but not for oral sex 0 6 (9) 11 (8)
Missing 5 (7) 1 (1) 1 (1)
Partner known to have gonorrhoea, n (%)
No 56 (81) 55 (85) 111 (83)
Yes 13 (19) 9 (14) 22 (16)
Not known 0 1 (2) 1 (1)
a Not mutually exclusive.
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TABLE 9 Clinical examination at baseline
Baseline examination
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
Height (cm)
Mean (SD) 176.1 (9.3) 176.4 (9.2) 176.3 (9.3)
Median (25th percentile, 75th percentile) 177 (170, 183) 178 (171, 183) 177 (170, 183)
Minimum, maximum 147, 198 106, 197 106, 198
Weight (kg)
Mean (SD) 77 (17.7) 76.2 (13.7) 76.6 (15.8)
Median (25th percentile, 75th percentile) 75 (66, 84.1) 75 (67, 83) 75 (66.6, 83)
Minimum, maximum 41, 193 49.2, 135 41, 193
BMI (kg/m2)
Mean (SD) 24.8 (5.2) 24.5 (4.5) 24.7 (4.9)
Median (25th percentile, 75th percentile) 23.7 (21.9, 26.9) 23.7 (21.5, 26.5) 23.7 (21.6, 26.7)
Minimum, maximum 16.7, 59.5 16.6, 46.4 16.6, 59.5
Women
Cervicitis, n (%)
No 58 (84) 56 (86) 114 (85)
Yes 8 (12) 5 (8) 13 (10)
Not known 3 (4) 4 (7) 7 (5)
Men and women
Evidence of genital discharge, n (%)
No 195 (54) 164 (46) 359 (50)
Yes 164 (45) 192 (54) 356 (49)
Not known 3 (1) 2 (1) 5 (1)
If yes, colour
Clear 19 (12) 21 (11) 40 (11)
Mucopurulent 62 (38) 79 (41) 141 (40)
Purulent 83 (51) 92 (48) 175 (49)
If yes, amount
Scanty 34 (21) 37 (19) 71 (20)
Average 68 (41) 87 (45) 155 (44)
Profuse 59 (36) 68 (35) 127 (36)
Missing 3 (1) 0 3 (1)
Other abnormality, n (%) 28 (8) 22 (6) 50 (7)
BMI, body mass index; SD, standard deviation.
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TABLE 10 Symptom assessment at baseline
Baseline symptoms
Treatment group
Total (N= 720)Ceftriaxone (N= 362) Gentamicin (N= 358)
Presence of any symptom at baseline, n (%) 230 (64) 241 (67) 471 (65)
Presence of symptom at baseline, n (%)
Genital discharge 153 (42) 179 (50) 332 (46)
Dysuria 125 (35) 154 (43) 279 (39)
Anorectal pain 15 (4) 8 (2) 23 (3)
Sore throat 53 (15) 52 (15) 105 (15)
Rectal discharge 12 (3) 10 (3) 22 (3)
Rectal bleeding 9 (2) 8 (2) 17 (2)
Tenesmus 8 (2) 4 (1) 12 (2)
Constipation 11 (3) 4 (1) 15 (2)
Intermenstrual bleeding (women only) 9 (2) 7 (2) 16 (2)
Post-coital bleeding (women only) 5 (1) 7 (2) 12 (2)
Other 26 (7) 26 (7) 52 (7)
Duration (days) of symptom at baseline, median (IQR)
Genital discharge 4.5 (2.5–8) 4 (2–7) 4 (2–7)
Dysuria 4 (2–7) 4 (2–7) 4 (2–7)
Anorectal pain 7 (5–21) 9.5 (3.5–21) 9 (4–21)
Sore throat 7 (3–14) 5.5 (2–14) 7 (2–14)
Rectal discharge 10.5 (3.5–24.5) 17.5 (10–28) 14 (4–28)
Rectal bleeding 28 (7–77) 17.5 (4.5–80.5) 21 (7–77)
Tenesmus 10.5 (3.5–24.5) 2 (2–11.5) 4 (2.5–21)
Constipation 14 (3–112) 45.5 (4–126) 14 (3–112)
Intermenstrual bleeding (women only) 14 (5–14) 14 (4–28) 14 (5–21)
Post-coital bleeding (women only) 7 (1–14) 14 (2–112) 10.5 (2–70)
Other 7 (2–28) 6.5 (3–28) 7 (2.5–28)
Hearing impairment, n (%)
No 354 (98) 347 (97) 701 (97)
Yes 8 (2) 11 (3) 19 (3)
If yes, severity
Grade 1 (mild) 6 (75) 10 (91) 16 (84)
Grade 2 (moderate) 0 1 (9) 1 (5)
Grade 3 (severe) 2 (25) 0 2 (11)
IQR, interquartile range.
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Compliance with the allocated intervention
Fourteen participants did not receive their allocated treatment: four (1%) in the ceftriaxone arm and 10
(3%) in the gentamicin arm. The reasons for this are given in Table 11. These 14 participants also did not
receive azithromycin. In addition, three participants were recorded as not receiving azithromycin alongside
their allocated treatment: one participant was recorded as not receiving azithromycin as they vomited
within 50 minutes of taking it; the other two participants had already been prescribed/provided with
azithromycin by another nurse practitioner and so did not receive it as part of trial treatment.
Of the 720 participants randomised, 624 (87%) attended their follow-up visit, 89% in the ceftriaxone
group and 84% in the gentamicin group (Table 12). The median time from randomisation to follow-up
was similar in both treatment groups, at 16 and 15 days in the ceftriaxone and gentamicin groups,
respectively, with an interquartile range (IQR) of 14–20 days.
Data sets
The ITT data set was defined as ‘participants as randomised’, regardless of adherence to the allocated
group and without imputation for missing data. There were 720 participants included in the ITT data set:
362 who were randomised to ceftriaxone and 358 who were randomised to gentamicin. All baseline
summaries and summaries/analyses of efficacy data are based on this data set. Follow-up data were
available for 624 participants: 322 in the ceftriaxone group and 302 in the gentamicin group.
The safety data set was defined as ‘all participants according to the treatment that they actually received’.
It comprised 706 participants: 358 who received ceftriaxone and 348 who received gentamicin. The
14 participants who had not received ceftriaxone or gentamicin were excluded from this data set but
the participants who did not receive azithromycin remained in this data set as they had received either
ceftriaxone or gentamicin. This data set was used to summarise safety data at follow-up. Follow-up data
were available for 618 participants: 320 who received ceftriaxone and 298 who received gentamicin.
TABLE 11 Compliance with the allocated intervention
Compliance
Treatment group, n (%)
Ceftriaxone (N= 362) Gentamicin (N= 358)
Full injection of trial medication administered
No 4 (1) 10 (3)
Yes 358 (99) 348 (97)
Reason for not taking trial medication, n
Allergic to penicillin 1 1
Allergic to azithromycin 0 1
Diagnosis of PID after randomisation 0 2
Diagnosis of BV after randomisation 1 1
Trial drug could not be found/out of stock 0 2
No injecting nurse available 1 1
Found to have hearing impairment after randomisation 1 0
Participant refused injection because of needle phobia 0 1
Unknown 0 1
Azithromycin taken
No 5 (1) 12 (3)
Yes 357 (99) 346 (97)
BV, bacterial vaginosis; PID, pelvic inflammatory disease.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
Primary outcome
The primary outcome – clearance of N. gonorrhoeae at all infected sites confirmed by a negative NAAT
2 weeks post treatment – was available for 598 (83%) participants overall: 306 (85%) and 292 (82%)
in the ceftriaxone and gentamicin groups, respectively.
The main reasons for not having evaluable data were participants not returning for their follow-up visit
and incorrect sampling at the follow-up visit (Table 13). At the start of the trial, a small number of
participants were not asked by the recruiting site to return for follow-up, in error. This occurred after they
TABLE 12 Completeness of follow-up
Follow-up attendance
Treatment group
Ceftriaxone (N= 362) Gentamicin (N= 358)
Attended follow-up visit, n (%) 322 (89) 302 (84)
Time from randomisation to follow-up visit, n (%)
< 14 days 4 (1) 3 (1)
14 days 101 (31) 124 (41)
15–21 days 162 (50) 121 (40)
22–28 days 27 (8) 34 (11)
5–6 weeks 24 (7) 12 (4)
> 6 weeks 4 (1) 8 (3)
Time (days) from randomisation to follow-up
Mean (SD) 18.5 (6.9) 18.4 (8.4)
Median (25th percentile, 75th percentile) 16 (14, 20) 15 (14, 20)
Primary outcome data available, n (%) 306 (85) 292 (82)
SD, standard deviation.
TABLE 13 Completeness of follow-up for primary outcome
Primary outcome
Treatment group
Ceftriaxone group (N= 362) Gentamicin group (N= 358)
Primary outcome available, n (%) 306 (85) 292 (82)
Primary outcome not available, n (%) 56 (15) 66 (18)
Reason primary outcome not available, n
Participant withdrew consent 1 0
Loss to follow-up 36 47
Incorrect sampling at follow-up 16 10
Other 3 9
Other reasons, n
Penicillin allergy 1 1
Ineligible post randomisation 1 2
Baseline test for gonorrhoea negative 1 1
No trial medication given 0 2
Did not attend appointments 0 3
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reported exclusion criteria post randomisation (e.g. penicillin allergy), tested negative for gonorrhoea at
baseline or did not receive trial medication. This was corrected by site training. Slightly more participants
in the gentamicin group failed to come back for their follow-up visit.
In total, of those with evaluable data for the primary outcome, 299 out of 306 (98%) participants in the
ceftriaxone group and 267 out of 292 (91%) participants in the gentamicin group had clearance of
gonorrhoea from all sites (Table 14).
The baseline characteristics for participants who had evaluable primary outcome data were similar between
the two treatment groups, with the exception of site of infection: 50% of participants in the ceftriaxone
group had a genital infection compared with 60% in the gentamicin group. For those randomised to
ceftriaxone, there were more men (89% vs. 79%) and more genital infections (64% vs. 50%) in the group
without clearance data than in the group with clearance data. For those randomised to gentamicin, there
were fewer men (71% vs. 84%) in the group without clearance data than in the group with clearance
data (see Appendix 3, Table 34).
The adjusted risk difference was –6.4% (gentamicin vs. ceftriaxone), with a 95% CI of –10.4% to –2.4%
(Table 15 and Figure 4). The lower 95% confidence limit (–10.4%) was < –5%, the predefined threshold
for determining non-inferiority. Therefore, non-inferiority was not demonstrated.
TABLE 14 Clearance of N. gonorrhoeae
Clearance
Treatment group, n (%)
Ceftriaxone (N= 362) Gentamicin (N= 358)
Participants with clearance data 306 (85) 292 (82)
Results of clearance data
Clearance of N. gonorrhoeae 299 (98) 267 (91)
Not cleared of N. gonorrhoeae 7 (2) 25 (9)
TABLE 15 Clearance rate of N. gonorrhoeae at 2 weeks post randomisation
Treatment group Clearance rate of N. gonorrhoeae (%)
Adjusted risk difference of
gentamicin vs. ceftriaxonea (%) 95% CI (%)
Ceftriaxone 98 –6.4 –10.4 to –2.4
Gentamicin 91
a Adjusted by site, using general linear model for binary outcome.
– 0.15 – 0.10 – 0.05 0 0.05
– 0.06 (– 0.10 to – 0.02)
Adjusted risk
difference (95% CI)
Favours ceftriaxone Favours gentamicin
FIGURE 4 Clearance of N. gonorrhoeae at 2 weeks post randomisation. The non-inferiority margin is –0.05.
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Sensitivity analyses for the primary outcome
Sensitivity analyses for the primary outcome are presented in Table 16 and Figure 5. Although the adjusted
risk differences varied between the different sensitivity analyses, all analyses performed were supportive of
the primary analysis, with the lower 95% confidence limits of the 95% CIs all being < –5%.
Secondary outcomes
Clearance of N. gonorrhoeae by infection site
Of the participants who had a genital infection, 98% in the ceftriaxone group and 94% in the gentamicin
group were cleared at their follow-up visit (Table 17 and Figure 6). The adjusted risk difference was –4.4%
(95% CI –8.7% to 0%). A greater proportion of participants with pharyngeal infection receiving ceftriaxone
had clearance at their follow-up visit (96%) than participants receiving gentamicin (80%). The adjusted risk
difference was –15.3% (95% CI –24.0% to –6.5%). Similarly, a greater proportion of participants with
rectal infection in the ceftriaxone group showed clearance (98%) than patients in the gentamicin group
(90%) (adjusted risk difference –7.8%, 95% CI –13.6% to –2.0%). Clearance at genital site by sex is also
provided in Appendix 3, Table 34.
Clinical resolution of symptoms
There was no evidence of any difference between the treatment groups in terms of resolution of
symptoms (Table 18). The 95% CIs for the adjusted risk differences are wide for those cases when the
number of participants experiencing some symptoms at baseline was small. For all 12 participants who had
post-coital bleeding, this symptom had resolved at 2 weeks post randomisation. These data are therefore
not included in Table 18. The complete summary data of symptoms at baseline and follow-up are included
in Appendix 3, Table 35.
TABLE 16 Sensitivity analyses for clearance of N. gonorrhoeae at 2 weeks post randomisation
Scenario
Treatment
group
Number of
participants
included in
analysis
Clearance
rate of N.
gonorrhoeae (%)
Adjusted risk
differencea (%) 95% CI (%)
Exclude those without any
positive samples at baseline
Ceftriaxone 268 98 –7.1 –11.4 to –2.8
Gentamicin 261 91
Exclude those who did not
receive allocated treatment
Ceftriaxone 304 98 –6.5 –10.5 to –2.4
Gentamicin 289 91
Exclude those who did not
have full required samples
taken at baseline
Ceftriaxone 269 98 –5.9 –10.0 to –1.8
Gentamicin 260 92
Assume missing clearance
data as not cleared
Ceftriaxone 362 83 –8.1 –14.1 to –2.1
Gentamicin 358 75
Assume missing clearance
data as cleared
Ceftriaxone 362 98 –5.3 –8.6 to –1.9
Gentamicin 358 93
Multiple imputation of
missing clearance data
Ceftriaxone 362 97 –5.1 –8.7 to –1.5
Gentamicin 358 92
Use local BD NAAT if AC2
NAAT not available
Ceftriaxone 317 97 –6.2 –10.2 to –2.2
Gentamicin 295 91
a Adjusted by site, using general linear model for binary outcome.
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– 0.15 – 0.10 – 0.05 0 0.05
Adjusted risk
difference (95% CI)
Favours ceftriaxone Favours gentamicin
– 0.06 (– 0.10 to – 0.02)
– 0.07 (– 0.11 to – 0.03)
– 0.07 (– 0.11 to – 0.02)
– 0.06 (– 0.10 to – 0.02)
– 0.08 (– 0.14 to – 0.02)
– 0.05 (– 0.09 to – 0.02)
– 0.05 (– 0.09 to – 0.02)
– 0.06 (– 0.10 to – 0.02)
Primary analysis
Exclude those without positive samples at baseline
Exclude those who did not receive allocated treatment
Exclude those who did not have full required samples taken 
    at baseline
Assume missing clearance data as not cleared
Assume missing clearance data as cleared
Multiple imputation of missing clearance data
Use local BD NAAT if AC2 NAAT is not available
FIGURE 5 Sensitivity analyses for clearance of N. gonorrhoeae at 2 weeks post randomisation. The non-inferiority margin is –0.05.
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TABLE 17 Clearance of N. gonorrhoeae by infection site
Clearance at infection site
Treatment group
Ceftriaxone Gentamicin
Genital infection N = 154 N = 174
Cleared of N. gonorrhoeae, n (%) 151 (98) 163 (94)
95% CI (%) 96 to 100 90 to 97
Not cleared of N. gonorrhoeae, n (%) 3 (2) 11 (6)
Risk difference (95% CI) for clearance (%) –4.4 (–8.7 to 0)
Pharyngeal infection N = 113 N = 102
Cleared of N. gonorrhoeae, n (%) 108 (96) 82 (80)
95% CI (%) 92 to 99 72 to 88
Not cleared of N. gonorrhoeae, n (%) 5 (4) 20 (20)
Risk difference (95% CI) for clearance (%) –15.3 (–24.0 to –6.5)
Rectal infection N = 137 N = 119
Cleared of N. gonorrhoeae, n (%) 134 (98) 107 (90)
95% CI 95 to 100 84 to 95
Not cleared of N. gonorrhoeae, n (%) 3 (2) 12 (10)
Risk difference (95% CI) for clearance (%) –7.8 (–13.6 to –2.0)
– 0.25 – 0.15 – 0.10 – 0.05 0 0.05
– 0.04 (– 0.09 to 0.00)
– 0.15 (– 0.24 to – 0.06)
– 0.08 (– 0.14 to – 0.02)
Genital
Clearance
Pharyngeal
Rectal
Adjusted risk
difference (95% CI)
Favours ceftriaxone Favours gentamicin
FIGURE 6 Clearance of N. gonorrhoeae by infection site. The non-inferiority margin is –0.05.
TABLE 18 Clinical resolution of symptoms in participants who had the symptom present at baseline
Symptom
Number of participants
included in analysis
Adjusted risk difference
(gentamicin vs. ceftriaxone)a (%) 95% CI (%)
Genital discharge 276 –0.1 –5.5 to 5.2
Dysuria 234 –7.7 –13.6 to 1.9
Sore throat 92 4.0 –7.4 to 15.4
Anorectal pain 20 –24.4 –62.5 to 13.7
Rectal bleeding 15 12.5 –10.4 to 35.4
Rectal discharge 20 –9.9 –43.7 to 23.9
Tenesmus 10 12.5 –10.4 to 35.4
Constipation 15 –12.6 –57.8 to 32.6
Intermenstrual bleeding (female only) 14 11.1 –9.0 to 31.6
a Adjusted by site.
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Frequency of nausea, vomiting, reduction in hearing, dizziness and rash
The frequencies of the expected side effects of gentamicin and ceftriaxone were summarised based on
the safety data set. This data set excluded the 14 participants who did not receive either ceftriaxone or
gentamicin. There were 358 participants who received ceftriaxone and 348 participants who received
gentamicin included in the safety data set. Of these participants, follow-up data were available for 618
participants: 320 who had received ceftriaxone and 298 who had received gentamicin.
Nausea
The percentages of participants experiencing nausea were similar in the ceftriaxone group [12% (38/320)]
and the gentamicin group [14% (41/298)]. In total, 2% of participants in each group had grade 2 nausea
(oral intake significantly decreased). All other reports of nausea were grade 1 (able to eat normally). The
time to onset of nausea from the time of injection was similar in both treatment groups, as was the
duration of nausea and the percentage of participants fully recovered by follow-up (95% in both
treatment groups).
Vomiting
The incidence of vomiting was low, with three participants (1%) in the ceftriaxone group and 12 (4%)
in the gentamicin group experiencing at least one episode. All participants in the ceftriaxone group
experienced grade 1 vomiting (one episode in 24 hours), whereas, in the gentamicin group, eight
participants (3% of the total number of participants) experienced grade 1 and four (1%) experienced
grade 2 vomiting (2–5 episodes in 24 hours).
Reduction in hearing
Five participants in the ceftriaxone group (2%) and three (1%) in the gentamicin group reported a mild
reduction in their hearing. Of these participants, one in each group had not fully recovered by their
follow-up visit.
Dizziness/unsteadiness
A total of 24 participants in the ceftriaxone group (7%) and 21 in the gentamicin group (7%) reported
dizziness or unsteadiness. In the ceftriaxone group, 20 reported grade 1 severity (not interfering with
function), three reported grade 2 severity (interfering with function but not interfering with daily activity)
and one reported grade 4 severity (bedridden or disabled) events. The grade 4 severity event was reported as
a SAE and was not considered to be related to the trial medication. In the gentamicin group, 19 participants
reported grade 1 severity and two participants reported grade 2 severity events.
Skin rashes
Five participants in the ceftriaxone group (2%) and 12 participants in the gentamicin group (4%) reported
skin rashes; all five participants in the ceftriaxone group and 11 out of the 12 participants in the gentamicin
group reported a grade 1 skin rash (localised skin eruption). One participant in the gentamicin group reported
a grade 2 skin rash (diffuse skin eruption covering ≤ 50% of the body surface area). All participants in the
ceftriaxone group had fully recovered by their follow-up visit, whereas 6 out of the 12 participants in the
gentamicin group had not fully recovered.
Injection pain
In total, 315 out of the 320 participants in the ceftriaxone group (98%) and 294 of the 298 participants in
the gentamicin group (99%) recorded injection pain. The median time for the pain to completely resolve
was slightly longer in the gentamicin group than in the ceftriaxone group (1.5 hours vs. 1 hour; IQR:
0–24 hours for the gentamicin group and 0–12 hours for the ceftriaxone group).
The results for all expected side effects of ceftriaxone and gentamicin are summarised in Table 19.
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TABLE 19 Summary of side effects following treatment
Side effect
Treatment group
Ceftriaxone
(N= 320)
Gentamicin
(N= 298)
Any nausea, n (%) 38 (12) 41 (14)
Severity, n (%)
Grade 1 (able to eat normally) 30 (9) 36 (12)
Grade 2 (oral intake significantly decreased) 8 (2) 5 (2)
Grade 3 (no significant intake or requiring i.v. fluids) 0 (0) 0 (0)
Time from injection to onset, n (%)
< 2 hours 22 (58) 24 (59)
2–6 hours 8 (21) 10 (24)
6–24 hours 4 (11) 3 (7)
1–3 days 2 (5) 2 (5)
> 3 days 2 (5) 2 (5)
Duration (hours)
Median (25th percentile, 75th percentile) 3 (1–9) 3 (1–24)
Minimum, maximum 1, 240 1, 240
Fully recovered, n (%)
No 2 (5) 2 (5)
Yes 36 (95) 39 (95)
Any vomiting, n (%) 3 (1) 12 (4)
Severity, n (%)
Grade 1 (1 episode in 24 hours) 3 (1) 8 (3)
Grade 2 (2–5 episodes in 24 hours) 0 (0) 4 (1)
Grade 3 (≥ 6 episodes in 24 hours or need for i.v. fluids) 0 (0) 0 (0)
Time from injection to onset, n (%)
< 2 hours 1 (33) 5 (42)
2–6 hours 0 (0) 1 (8)
6–24 hours 0 (0) 1 (8)
1–3 days 1 (33) 3 (25)
> 3 days 1 (33) 2 (17)
Duration (hours)
Median (25th percentile, 75th percentile) 1 (1–3) 1.5 (1–36)
Minimum, maximum 1, 3 1, 72
Fully recovered, n (%)
No 0 0
Yes 3 (100) 12 (100)
continued
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TABLE 19 Summary of side effects following treatment (continued )
Side effect
Treatment group
Ceftriaxone
(N= 320)
Gentamicin
(N= 298)
Any reported reduction in hearing, n (%) 5 (2) 3 (1)
Severity, n (%)
Mild 5 (2) 3 (1)
Moderate 0 (0) 0 (0)
Severe 0 (0) 0 (0)
Duration (hours)
Median (25th percentile, 75th percentile) 144 (72–264) 96 (2–336)
Minimum, maximum 12, 504 2, 336
Time from injection to onset, n (%)
< 2 hours 1 (20) 0 (0)
2–6 hours 0 (0) 0 (0)
6–24 hours 0 (0) 1 (33)
1–3 days 2 (40) 1 (33)
> 3 days 2 (40) 1 (33)
Fully recovered, n (%)
No 1 (20) 1 (33)
Yes 4 (80) 2 (67)
Any reported dizziness or unsteadiness, n (%) 24 (7) 21 (7)
Severity, n (%)
Grade 1 (not interfering with function) 20 (6) 19 (6)
Grade 2 (interfering with function but not interfering with daily activities) 3 (1) 2 (1)
Grade 3 (interfering with daily activities) 0 (0) 0 (0)
Grade 4 (bedridden or disabled) 1 (0) 0 (0)
Duration (hours)
Median (25th percentile, 75th percentile) 2 (1–15) 4 (1–24)
Minimum, maximum 1, 72 0, 168
Time from injection to onset, n (%)
< 2 hours 13 (54) 10 (48)
2–6 hours 5 (21) 5 (24)
6–24 hours 2 (8) 4 (19)
1–3 days 0 (0) 1 (5)
> 3 days 4 (17) 1 (5)
Fully recovered, n (%)
No 1 (4) 2 (10)
Yes 23 (96) 19 (90)
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Other adverse events
Table 20 shows that the percentage of participants reporting other AEs at their follow-up visit was similar
in both treatment groups: 15% (48/320) in the ceftriaxone group and 13% (38/298) in the gentamicin
group, with the majority of AEs being mild. The most frequent class of AEs reported was gastrointestinal
disorders: 14 participants reported these in the ceftriaxone group (4%) and 22 participants reported these
in the gentamicin group (7%). The majority of these gastrointestinal disorders consisted of diarrhoea.
Nervous system disorders were reported by 10 participants in the ceftriaxone group and three participants
in the gentamicin group. The events that coded to nervous system disorders were headaches (six in the
ceftriaxone group and one in the gentamicin group), dizziness (one in the ceftriaxone group and one in
the gentamicin group), migraine (one in the ceftriaxone group), lethargy (one in the ceftriaxone group and
one in the gentamicin group) and Bell’s palsy (one in the ceftriaxone group).
Five per cent of AEs in the ceftriaxone group and 6% in the gentamicin group were reported to be related
to the trial medication. Three AEs (only one of which was related to the trial medication) were reported to
be severe: one in the ceftriaxone group and two in the gentamicin group. These were ‘diarrhoea’, ‘grade 4
dizziness’ and ‘sickness’. Of these, the grade 4 dizziness was also classified as a SAE. All were resolved by
the follow-up visit.
The SAE was grade 4 dizziness in a participant in the ceftriaxone group, which had occurred 4 days after
randomisation. It was considered to be unrelated to the trial medication and was resolved before the
follow-up visit.
A full list of AEs is provided in Appendix 3.
TABLE 19 Summary of side effects following treatment (continued )
Side effect
Treatment group
Ceftriaxone
(N= 320)
Gentamicin
(N= 298)
Any new skin rash, n (%) 5 (2) 12 (4)
Severity, n (%)
Grade 1 (localised skin eruption) 5 (2) 11 (4)
Grade 2 (diffuse skin eruption covering ≤ 50% of body surface area) 0 (0) 1 (0)
Grade 3 (generalised skin eruption covering > 50% of body surface area) 0 (0) 0 (0)
Duration (hours)
Median (25th percentile, 75th percentile) 24 (24–24) 72 (36–324)
Minimum, maximum 6, 72 4, 744
Fully recovered, n (%)
No 0 (0) 6 (50)
Yes 5 (100) 6 (50)
Injection pain, n (%) 315 (98) 294 (99)
How long (hours) did it take to completely resolve the pain associated with injection?
Median (25th percentile, 75th percentile) 1 (0–12) 2 (0–24)
Minimum, maximum 0, 240 0, 432
i.v., intravenous.
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Creatinine level and estimated glomerular filtration rate
The percentage of participants who had an increase in creatinine level of > 30% was similar in both
treatment groups: 3% (10/358) in the ceftriaxone group and 3% (9/348) in the gentamicin group (Table 21).
The follow-up creatinine value for 9% (28/304) of participants in the ceftriaxone group and 13% (38/289) of
participants in the gentamicin group exceeded the upper limit of normal, as defined by their local laboratory.
Changes in eGFR between baseline and follow-up were similar in both arms (see Table 21).
The shift plots in Figures 7 and 8 demonstrate the shifts in creatinine level from baseline to visit 2. AEs
relating to creatinine were reported for seven participants: five who had received ceftriaxone and two
who had received gentamicin. All were mild and five out of the seven AEs were not thought to be related
to trial medication. The grid lines represent the lowest of the lower bounds and highest of the upper
bounds of normality between all of the local laboratories. The diagonal line represents the line of unity
(no change).
TABLE 20 Summary of AEs
AEs
Treatment group
Ceftriaxone (N= 320) Gentamicin (N= 298)
Total number of AEs 54 43
Total number of AEs thought to be related to trial medication 48 38
Participants with any AE, n (%) 48 (15) 38 (13)
Participants with AE related to trial medication, n (%) 15 (5) 17 (6)
Participants with any SAE, n (%) 1 (<0.5) 0 (0)
Severity of AE, n (%)
Mild 45 (83) 35 (81)
Moderate 8 (15) 6 (14)
Severe 1 (2) 2 (5)
MedDRA31 SOC codes,a n (%)
Ear and labyrinth disorders 3 (3) 0 (0)
Gastrointestinal disorders 14 (14) 22 (22)
General disorders and administration site conditions 6 (6) 3 (3)
Infections and infestations 7 (7) 5 (5)
Investigations 5 (5) 2 (2)
Metabolism and nutrition disorders 0 (0) 2 (2)
Musculoskeletal and connective tissue disorders 2 (1) 4 (4)
Neoplasms benign, malignant and unspecified (including
cysts and polyps)
1 (1) 0 (0)
Nervous system disorders 10 (10) 3 (3)
Pregnancy, puerperium and perinatal conditions 1 (1) 0 (0)
Psychiatric disorders 1 (1) 0 (0)
Respiratory, thoracic and mediastinal disorders 3 (3) 1 (1)
Skin and subcutaneous tissue disorders 1 (1) 1 (1)
SOC, system organ classes.
a Number of participants are in parentheses.
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TABLE 21 Summary of creatinine levels and eGFR pre and post treatment
Creatinine levels and eGFR
Treatment group
Ceftriaxone
(N= 358)
Gentamicin
(N= 348)
Creatinine level
At baseline (µmol/l)
Mean (SD) 78.7 (15.4) 78.3 (15.8)
N 341 329
At 2 weeks post treatment (µmol/l)
Mean (SD) 79.7 (14.4) 80.2 (15.6)
N 304 289
Change in creatinine level, n (%)
Number of participants who met clinically important change from baseline to
2 weeks post treatmenta
10 (3) 9 (3)
Number of participants who exceeded upper limit of normal value at 2 weeks
post treatmentb
27 (7) 38 (11)
eGFR (ml/minute/1.73m2)
At baseline, mean (SD) 110.6 (18.2) 111.5 (17.7)
At 2 weeks post treatment, mean (SD) 109.2 (17.4) 108.7 (17.9)
Change in eGFR at 2 weeks post treatment, median (IQR) –1.3 (–6.7 to 4.3) –1.4 (–6.9 to 3.7)
SD, standard deviation.
a Defined as a change of > 30% from baseline.
b There are specific lower and upper limits of normal values for each individual local site.
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FIGURE 8 Shift plot of pre- and post-treatment creatinine levels in females.
C
re
at
in
in
e 
le
ve
l a
t 
fo
llo
w
-u
p
 (
µ
m
o
l/l
)
20 40 60 80 100 120 140 160
Creatinine level at baseline (µmol/l)
20
40
60
80
100
120
140
160
Ceftriaxone
Gentamicin
Treatment group
FIGURE 7 Shift plot of pre- and post-treatment creatinine levels in males.
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Tolerability of injection
Injection site pain
The VAS score (1–100) completed immediately after injection with the trial treatment showed higher mean
and median values (i.e. more pain) for the gentamicin group (Table 22). The pain scores recalled at the
2-week follow-up visit were also higher in the gentamicin group.
Minimum inhibitory concentrations
Gentamicin
Figure 9 shows the MIC distribution for gentamicin for the 367 participants for whom isolate data were
available.
Figure 10 shows the gentamicin MICs of isolates from participants who received gentamicin and achieved
microbiological clearance (as defined by a negative AC2 NAAT at all previously infected sites, 2 weeks after
treatment). Data were available for 149 participants. The proportion who had clearance of N. gonorrhoeae
at all sites was 90%. All isolates from non-responders had a MIC of 4 mg/l.
TABLE 22 Summary of VAS score by treatment arm
VAS score
Treatment group
Ceftriaxone (N= 362) Gentamicin (N= 358)
VAS score for injection site pain immediately after injection
Mean (SD) 21.2 (19.4) 36 (23.2)
Median (25th percentile, 75th percentile) 15 (6, 30) 31.5 (18, 53.5)
Minimum, maximum 0, 86 0, 100
N 353 348
Recalled VAS score for pain at baseline injection after 2 weeks
Mean (SD) 20.4 (20.5) 34.3 (25)
Median (25th percentile, 75th percentile) 15 (4, 30) 31 (13, 55)
Minimum, maximum 0, 100 0, 100
N 313 295
SD, standard deviation.
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FIGURE 9 Gentamicin overall MIC distribution (mg/l) at baseline (all participants with sample data).
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Ceftriaxone
Figure 11 shows the MIC distribution for ceftriaxone for the 364 participants for whom isolate data were
available. Fifty-nine participants (16%) harboured isolates with MIC values of ≤ 0.002 mg/l.
Figure 12 shows the ceftriaxone MICs of isolates from participants who received ceftriaxone and achieved
microbiological clearance (as defined by a negative AC2 NAAT at all previously infected sites, 2 weeks
after treatment). Data were available for 170 participants. The proportion of these participants who had
clearance of N. gonorrhoeae at all sites was 96%. The six non-responders had MICs ranging from ≤ 0.002
to 0.008 mg/l.
Azithromycin
Figure 13 shows the MIC distribution for azithromycin for the 357 participants for whom isolate data were
available. The distribution of MICs ranged from 0.032 to 4 mg/l.
Figure 14 shows the azithromycin MICs of isolates from participants who received azithromycin and
achieved microbiological clearance (as defined by a negative AC2 NAAT at all previously infected sites,
2 weeks after treatment). Data were available for 305 participants. The proportion of these participants
who had clearance of N. gonorrhoeae at all sites was 93%. The two non-respondents had MICs ranging
from 0.064 to 1 mg/l.
Further plots showing the MIC distribution by infection site are available in Appendix 3.
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FIGURE 10 Distribution of gentamicin MIC (mg/l) for participants who received gentamicin, by clearance at 2 weeks
post treatment.
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FIGURE 11 Ceftriaxone overall MIC distribution (mg/l) at baseline (all participants with sample data).
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FIGURE 12 Distribution of ceftriaxone MIC (mg/l) for participants who received ceftriaxone, by clearance at 2 weeks
post treatment.
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FIGURE 13 Azithromycin overall MIC distribution (mg/l) at baseline (all participants with sample data).
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FIGURE 14 Distribution of azithromycin MIC (mg/l) for all participants, by clearance at 2 weeks post treatment.
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Medications taken during the trial
A similar proportion of participants in both treatment arms took additional antibiotics in the period from
randomisation to follow-up (Table 23).
Other antibiotics taken during the trial
A listing of other antibiotics that participants took during the trial is provided in Appendix 3.
Sexual behaviour and condom use during the trial
Tables 24 and 25 show the sexual behaviour of males and females, respectively, after receiving their trial
medication. Out of 257 males in the ceftriaxone group and 251 males in the gentamicin group, 98 (38%)
and 88 (35%), respectively, reported having had sex between receiving their randomised treatment and
the 2-week follow-up. Of these, 40 males out of 98 (41%) and 37 males out of 88 (42%), respectively,
never used a condom. Out of 65 females in the ceftriaxone group and 50 females in the gentamicin
group, 20 (31%) and 16 (32%), respectively, reported having had sex between receiving trial treatment
and the 2-week follow-up visit. Of these, 7 females out of 20 (35%) and 10 females out of 16 (63%)
reported never using a condom. The risk of reinfection as a result of having sex in the follow-up period
and the failure to use condoms in this period was therefore deemed similar in the two treatment groups.
Protocol deviations
Protocol deviations were reported in 121 out of 362 (33%) participants receiving ceftriaxone and 124 out
of 358 (35%) participants receiving gentamicin; the majority of deviations were considered minor. There
were only two major deviation categories: not receiving treatment according to randomisation and not
fulfilling the eligibility criteria. Fourteen participants did not receive treatment according to randomisation
and 20 deviations from the eligibility criteria were reported for 18 participants. These included participants
being found to have contraindications to trial medication and having a disallowed concomitant disease.
A list of the protocol deviations recorded on the deviation log can be found in Appendix 3.
TABLE 23 Additional antibiotic use during trial
Antibiotic
Treatment group, (n)
Ceftriaxone (N= 362) Gentamicin (N= 358)
Taken at least one non-trial antibiotic 13 16
Azithromycin 2 1
Doxycycline 9 9
Ceftriaxone 0 3
Metronidazole 1 1
Trimethoprim 0 1
Ofloxacin 0 1
Clarithromycin 1 0
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TABLE 24 Sexual history between randomisation and 2-week follow-up visit (males)
Sexual history
Treatment group
Ceftriaxone (N= 257) Gentamicin (N= 251)
Sexual contact since receiving treatment for gonorrhoea
No, n (%) 157 (61) 163 (65)
Yes, n (%) 98 (38) 88 (35)
Not known, n (%) 2 (1) 0
If yes, number of partners
Median (25th percentile, 75th percentile) 1 (1, 2) 1 (1, 2)
Minimum, maximum 1, 6 1, 13
Previous partners
Median (25th percentile, 75th percentile) 1 (0, 1) 1 (0, 1)
Minimum, maximum 0, 3 0, 5
New partners
Median (25th percentile, 75th percentile) 1 (0, 1) 0 (0, 1)
Minimum, maximum 0, 6 0, 12
Number of episodes of sexual contact since receiving treatment for gonorrhoea
Median (25th percentile, 75th percentile) 2 (1, 3) 2 (1, 4)
Minimum, maximum 1, 15 1, 20
Type of sexual contact,a n (%)
Genital–genital 48 (19) 43 (17)
Genital–oral 73 (28) 67 (27)
Oral–genital 67 (26) 61 (24)
Genital–anal 51 (20) 47 (19)
Anal–genital 36 (14) 42 (17)
Oral–anal 24 (9) 29 (12)
Anal–oral 22 (9) 25 (10)
Digital–anal 26 (10) 26 (10)
Anal–digital 21 (8) 21 (8)
Use of condoms since receiving treatment for gonorrhoea, n (%)
No 40 (15) 37 (15)
Yes, partially 6 (2) 11 (4)
Yes, consistently, including for oral sex 15 (6) 7 (3)
Yes, consistently, but not for oral sex 37 (14) 33 (13)
Unknown 2 (1) 0
N/A 157 (61) 163 (65)
N/A, not applicable.
a Not mutually exclusive.
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TABLE 25 Sexual history between randomisation and 2-week follow-up visit (females)
Sexual history
Treatment group
Ceftriaxone (N= 65) Gentamicin (N= 50)
Sexual contact since receiving treatment for gonorrhoea
No, n (%) 45 (69) 34 (68)
Yes, n (%) 20 (31) 16 (32)
If yes, number of partners
Median (25th percentile, 75th percentile) 1 (1, 1) 1 (1, 1)
Minimum, maximum 1, 5 1, 2
Previous partners
Median (25th percentile, 75th percentile) 1 (0.5, 1) 1 (1, 1)
Minimum, maximum 0, 1 0, 1
New partners
Median (25th percentile, 75th percentile) 0 (0, 1) 0 (0, 0.5)
Minimum, maximum 0, 5 0, 1
Number of episodes of sexual contact since receiving treatment for gonorrhoea
Median (25th percentile, 75th percentile) 1 (1, 2.5) 1 (1, 2.5)
Minimum, maximum 1, 14 1, 4
Type of sexual contact,a n (%)
Genital–genital 19 (29) 13 (26)
Genital–oral 5 (8) 3 (6)
Oral genital 8 (12) 3 (6)
Genital–anal 0 0
Anal–genital 1 (2) 1 (2)
Oral–anal 0 0
Anal–oral 0 0
Digital–anal 0 0
Anal–digital 0 0
Use of condoms since receiving treatment for gonorrhoea, n (%)
No 7 (11) 10 (20)
Yes, partially 5 (8) 2 (4)
Yes, consistently, including for oral sex 3 (5) 2 (4)
Yes, consistently, but not for oral sex 5 (8) 2 (4)
Unknown 0 0
N/A 45 (69) 34 (68)
N/A, not applicable.
a Not mutually exclusive.
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Chapter 4 Economic evaluation of gentamicin
compared with ceftriaxone in the treatment of
gonorrhoea
Introduction and aims
The aim of the economic evaluation was to compare the costs and outcomes associated with the current
standard treatment, ceftriaxone, in the treatment of gonorrhoea with those of the proposed alternative
treatment, gentamicin. The primary aim of the G-TOG trial was to determine whether or not gentamicin
is an acceptable alternative to ceftriaxone in the treatment of gonorrhoea. There are several scenarios in
which a decision might be taken to use an alternative treatment. For example, the use of an alternative
antibiotic might be recommended to preserve the effectiveness of the current standard treatment, as
antibiotic resistance is linked to consumption.36 In addition, an alternative treatment might be needed in
the context of developing antimicrobial resistance (AMR) to the current standard treatment, as has
happened repeatedly with gonorrhoea over the last 70–80 years.37
The G-TOG trial was designed as a non-inferiority trial to assess whether or not the rate of microbiological
clearance of N. gonorrhoeae in participants treated with gentamicin is non-inferior to the rate of
microbiological clearance in participants treated with ceftriaxone. The economic analysis, therefore,
focused on establishing whether or not the use of gentamicin rather than ceftriaxone is cost neutral in the
treatment of gonorrhoea, in which case gentamicin could be used as a substitute for ceftriaxone without
additional resource implications. This involved the examination of costs and resource use to determine
whether or not there were any differences between the two treatments.
Methods
Overview
A cost-effectiveness analysis (CEA) was undertaken from the perspective of the NHS. The main outcome
considered was the clearance of gonorrhoea, as this was the primary outcome of the trial. A health-care
perspective was deemed to be the most relevant as the RCT is concerned with the non-inferiority of
gentamicin in the treatment of gonorrhoea; hence, the costs to the NHS associated with the two
treatments need to be assessed. A within-trial economic evaluation was undertaken that reflected the
objectives of the trial and the short follow-up period.
A simple decision tree was deemed to be the most suitable way of presenting the alternative patient
pathways and synthesising the available data. The model was necessary in order to analyse alternative
patient pathways, particularly in the sensitivity analyses, and collate available data. A decision-analytic
model involves using mathematical relationships to set out the consequences that are associated with the
different policy options under consideration.38 This allows the costs and outcomes for each option to be
evaluated, taking into account the probability of the consequences. Data on resource use and costs were
collected prospectively via trial reporting mechanisms and additional data were sourced from the literature.
Model structure
A decision tree model was developed using TreeAge Pro 2016 (TreeAge Software, Inc., Williamstown,
MA, USA). The structure was informed by the trial objectives and patient pathways were indicated by the
clinical data. As shown in Figure 15, participants entered the model at the point of randomisation to
receive the alternative treatment (gentamicin) or the standard treatment (ceftriaxone). Following the initial
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course of antibiotic treatment, participants either received additional NHS care [e.g. general practitioner (GP)
visit] or did not access care. At 2 weeks post treatment, participants either were cleared of N. gonorrhoeae
at all sites, confirmed by a negative NAAT, or were not cleared and required further treatment.
If clearance of N. gonorrhoeae at all sites was not confirmed (at 2 weeks post treatment), participants
were treated with a further course of antibiotics. For the purposes of the economic evaluation, the
base-case analysis followed current guidelines and it was assumed that all participants who were not
cleared of infection would be treated with a course of ceftriaxone. However, in the sensitivity analyses,
alternative scenarios were also explored, including the use of alternative antibiotic treatments when
participants were not cleared of the infection at all sites.
Clinical data
The primary outcome of the economic evaluation reflected the primary outcome of the trial – the clearance
of N. gonorrhoeae at all infected sites (confirmed by a negative NAAT) at 2 weeks post treatment (Table 26).
The primary approach to analysis was ITT without imputation of missing outcome data, as specified in the SAP.
Data were also collected on whether or not participants required further NHS care following the initial treatment.
G-TOG trial
Ceftriaxone
No NHS care
received
between
initial
treatment and
2-week check-up
NHS care
received
between
initial
treatment and
2-week check-up
Cleared of 
N. gonorrhoeae
at 2 weeks
Not cleared
Not cleared
Not cleared
Not cleared
Cleared of 
N. gonorrhoeae
at 2 weeks
Cleared of 
N. gonorrhoeae
at 2 weeks
Cleared of 
N. gonorrhoeae
at 2 weeks
No NHS care
received
between
initial
treatment and
2-week check-up
NHS care
received
between
initial
treatment and
2-week check-up
Gentamicin
FIGURE 15 Model structure.
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Treatment costs
Trial participants allocated to the gentamicin arm received 240 mg of gentamicin as a single i.m. injection.
This was obtained from three 80-mg ampoules, with an estimated cost of £1 per ampoule [£3 overall,
estimated using the British National Formulary (BNF)],39 as shown in Table 27. Participants allocated to the
ceftriaxone arm received a 500-mg dose. Ceftriaxone was purchased in units of 1 g and mixed with 4 ml
(1%) of lidocaine solution. Only half of the preparation was administered to the participant (half was
discarded); we therefore included costs for one vial of 1 g of ceftriaxone powder (£1.10) per participant
and two 2-ml lidocaine ampoules (£0.22 per ampoule).39 Hence, the initial costs associated with
gentamicin treatment were higher than those associated with the current standard treatment, ceftriaxone.
Other equipment (such as syringes) would be required by both arms of the trial and so these costs were
not included. In both trial arms, participants received a single oral dose of azithromycin, an initial
consultation with a health-care professional and a follow-up visit. These costs were excluded from the
analysis as they were incurred equally across the trial arms.
To check that there was no difference in the length of time required for delivery of the treatment therapy,
a survey was undertaken with research nurses involved in the delivery of the two treatments. The survey
aimed to check whether or not the delivery of the treatment and the length of the consultation were
affected by the drug that was being administered. The survey received responses from 21 nurses who
were administering injections. The majority of nurses (17 respondents, 81%) stated that there was no
difference in the time taken to administer the two treatments. Just four nurses (19%) responded that there
was a difference, all of whom stated that appointments to administer gentamicin were longer than those
to administer ceftriaxone. The main reason given for the longer time needed to administer gentamicin was
the increased pain associated with gentamicin injections (given as a reason by three of the nurses who felt
that gentamicin took longer to administer). Two nurses stated that appointments to administer gentamicin
took 0–5 minutes longer and two stated that an additional time of up to 10 minutes was needed. Given
the survey results, for the base-case analysis additional time was not included to administer the gentamicin
treatment; however, increased time was explored as part of the sensitivity analysis.
TABLE 26 Probabilities used in the decision-tree model
Treatment group description Trial data, n/N Probability Distribution
Ceftriaxone
Requiring NHS treatment after the initial visit 10/322 0.03 Beta
Not requiring NHS treatment after the initial visit 312/322 0.97 Beta
Clearance of N. gonorrhoeae 299/306 0.98 Beta
Not cleared of N. gonorrhoeae 7/306 0.02 Beta
Gentamicin
Requiring NHS treatment after the initial visit 8/302 0.03 Beta
Not requiring NHS treatment after the initial visit 294/302 0.96 Beta
Clearance of N. gonorrhoeae 267/292 0.91 Beta
Not cleared of N. gonorrhoeae 25/292 0.09 Beta
TABLE 27 Trial treatments
Resource use Cost item Base-case value (£) Distribution Source
Gentamicin treatment Per participant 3.00 Gamma BNF39
Ceftriaxone treatment Per participant 1.54 Gamma BNF39
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NHS resource use and costs incurred after initial treatment
NHS resource use by participants was collected during the trial at all participating sites using a form
completed by a nurse/assessor. Data were collected on whether or not participants had visited their
GP/nurse at their general practice, a GP out-of-hours service, health professionals at a sexual health clinic or
an accident and emergency (A&E) department and on the use of other services. Data were also collected on
whether or not participants were prescribed other medication (other than the trial treatment). In addition,
details of any AEs and associated resource use were recorded. Unit cost estimates were applied to resource
use data to generate individual-level cost estimates. The sources of unit costs included routine and published
literature (e.g. Unit Costs of Health and Social Care 201640).
Resource use was similar across trial arms, with the main resources that were used relating to GP visits and
sexual health centre visits (Table 28). No participants reported that they had been hospitalised during the
trial or attended A&E.
Further treatment costs owing to non-clearance of infection
Within the trial, when infection was not cleared at all sites (as indicated by a NAAT), further treatment
was given. Participants in the gentamicin arm were assumed to be treated with ceftriaxone (unless there
was a contraindication for this treatment). Participants in the ceftriaxone arm were assumed to have been
given a second course of ceftriaxone unless the culture demonstrated resistance to this treatment. For the
purposes of the economic evaluation, it was assumed that in both trial arms, when infection was not
cleared at 2 weeks post treatment, a sexual health clinic appointment would be needed and that a course
of the standard treatment (ceftriaxone) would be given (Table 29). This was to reflect current guidelines;8
other scenarios were explored in the sensitivity analysis.
Analysis
The within-trial analysis took the form of a CEA, with results reported in terms of the cost per participant
successfully treated (measured in terms of microbial clearance of N. gonorrhoeae at all infected sites,
2 weeks post treatment). As the trial was concerned with the immediate post-treatment period of 2 weeks,
discounting was not undertaken. All costs are given in Great British pounds for 2015/16.
TABLE 28 NHS resource use after initial treatment and before the 2-week follow-up
Resource use Cost item
Unit
cost (£)
Treatment group (n) Total cost (£)
Ceftriaxone Gentamicin Ceftriaxone Gentamicin
GP consultation Per visit 36.00 6 3 216.00 108.00
Sexual health clinic: health
advisor consultation
Per visit 93.00a 1 2 93.00 186.00
Sexual health clinic: doctor
consultation
Per visit 130.00b 5 4 650.00 520.00
NHS 111 call Per call 6.10c 1 1 6.10 6.10
Total costs 965.00 820.10
Total number of patients
accessing additional treatment
10 8
Total cost per patient
accessing additional treatment
95.60 102.51
a Assumed to be equivalent to non-consultant-led family planning clinic – first appointment (NHS Reference Costs
2015 to 201641).
b Assumed to be equivalent to consultant-led genitourinary consultation – first-appointment (NHS Reference Costs
2015 to 201641).
c Assumed to be equivalent to nurse-led telephone consultation.40
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Sensitivity analysis
Both deterministic and probabilistic sensitivity analyses were undertaken to explore the uncertainty in the
parameter estimates on the results produced by the model.42 In the deterministic sensitivity analysis, one
or more parameters were varied while keeping the others at their baseline value. Deterministic analysis can
help to identify which values are important in leading to a particular decision and can help to identify
threshold values.43,44
A range of deterministic sensitivity analyses was carried out. First, the cost of the interventions was varied
to reflect the purchase of different solutions/equipment based on prices reported in the BNF.39 Second, the
costs of additional treatment for those without clearance of N. gonorrhoeaewas varied to take into account
different scenarios for the development of AMR in gonorrhoea. The cost was increased to reflect a scenario in
which two further treatments of ceftriaxone were given and two follow-up visits to a clinic. Third, the rates of
clearance for gonorrhoea were varied to reflect different rates at different sites, using the lowest and highest
95% CIs reported in Table 17 for different sites. Fourth, the time taken to administer the gentamicin treatment
was varied to reflect the responses of a minority of nurses in the survey who indicated that gentamicin
injections took longer to administer. The cost of treatment was increased to take into account a scenario in
which an additional 10 minutes would be needed to administer gentamicin than to administer ceftriaxone,
assuming that the cost of the time of the nurse administering the treatment would be equivalent to that of a
GP nurse.40
A probabilistic sensitivity analysis (PSA) was also undertaken to allow uncertainty to be explored more
comprehensively. A PSA involves varying all parameters simultaneously and sampling multiple sets of
parameter values from defined probability distributions. A Monte Carlo simulation was used to sample from
the distributions; this involved 1000 repeated random draws to analyse how variation in the parameters
used in the model would affect the results. Beta distributions were used for binomial data and gamma
distributions were used for costs, in line with recommendations for specifying distributions for parameters.42
Results
The results of the analysis are shown in Table 30. A higher proportion of participants treated with
ceftriaxone were cleared of infection with N. gonorrhoeae (98%) than participants treated with gentamicin
TABLE 29 Costs of further treatment for participants when infection was not cleared
Resource use Cost item Unit cost (£) Source
Sexual health clinic: nurse/health advisor
consultation
Per visit 93.00a NHS Reference Costs 2015 to 201641
Second course of antibiotic treatment Per participant 1.54b NHS Reference Costs 2015 to 201641
Total costs 94.54
a Assumed to be equivalent to non-consultant-led family planning clinic – first appointment.
b Assumes one injection of ceftriaxone.
TABLE 30 Summary of the results of the base-case analysis
Treatment group Average cost (£) per participant (95% CI)
% cleared of infection at 2 weeks
post treatment ICER
Ceftriaxone 6.72 (1.36 to 17.84) 98 Dominates
Gentamicin 13.90 (2.47 to 37.34) 91
ICER, incremental cost-effectiveness ratio.
DOI: 10.3310/hta23200 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 20
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ross et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
(91%). The average participant costs associated with gentamicin were higher than those associated with
ceftriaxone. The main difference in costs related to the need for additional consultations and treatment for
participants who were not successfully cleared of infection at all sites (at 2 weeks post treatment). Hence,
the analysis found that treatment with gentamicin is not non-inferior to ceftriaxone and that it is not cost
neutral. The average cost per participant treated was £13.90 for gentamicin, compared with £6.72 for
ceftriaxone.
The results of the one-way deterministic sensitivity analyses are shown in Table 31. First, the results
arising from varying the costs associated with the antibiotic treatments are presented. The costs associated
with antibiotics might increase if penalties were introduced to discourage their use to slow down the
development of AMR. As expected, increasing the costs of the treatments increased the overall costs per
participant treated in both arms. Second, results from increasing the costs of additional treatment for those
without clearance of N. gonorrhoeae 2 weeks after treatment are shown. It is evident that this increased
overall costs for both trial arms, but particularly for the gentamicin arm as a result of the higher proportion
of participants in this arm who were not cleared of infection. The results for the third scenario show that
varying the rates of clearance to reflect the results at different sites (see Table 31) affects the relative
cost-effectiveness of the treatments. If the rates for clearance of genital infection are used, ceftriaxone still
dominates, but the difference in cost per participant between the groups is smaller. Clearance rates for
gentamicin would need to be higher than those for ceftriaxone for gentamicin to be cost neutral, owing to
the higher costs associated with gentamicin treatment. In the final scenario, increasing the costs associated
with administering the gentamicin treatment led to increased costs for the gentamicin arm.
The scatterplot in Figure 16 shows the results of the PSA involving 1000 simulations. It is evident that
the majority of the simulations generated did not show that gentamicin was non-inferior to ceftriaxone
and that the costs of gentamicin were shown to be higher. A large proportion of the points are in the
north-west quadrant, indicating that treatment with ceftriaxone dominates treatment with gentamicin
(gentamicin is not shown to be non-inferior and is unlikely to be cost neutral).
TABLE 31 Deterministic sensitivity analysis: selected results
Deterministic sensitivity analysis scenarios
Value
Treatment group, average cost
per participant (£)
Original Revised Ceftriaxone Gentamicin
Base case – – 6.72 13.90
(1) Varying the cost (£) of antibiotics
Gentamicin 3.00 1.54–12.00 12.44–22.90
Ceftriaxone 1.54 1.00–9.58 6.15–14.92
(2) Increasing the cost (£) of additional treatment for
those without clearance of N. gonorrhoeae
94.54 247.62 10.20 26.92
(3) Varying the rates of clearance of
N. gonorrhoeae
Gentamicin arm (%) 91 72–97 32.55–8.66
Ceftriaxone arm (%) 98 92–100 10.16–4.54
(4) Increasing the cost (£) of gentamicin treatment
(longer consultation time)
3.00 9.00 19.90
Note
Costs are in Great British pounds (2015/16).
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Discussion
The results show that gentamicin is likely to be more costly than ceftriaxone in the treatment of gonorrhoea.
Currently, it is not shown that gentamicin is non-inferior to ceftriaxone in the treatment of gonorrhoea, nor
is there evidence that it is cost neutral.
A major limitation of the economic analysis is that it was necessarily restricted because it was not possible
to fully take into account the potential costs associated with AMR in gonorrhoea, nor the potential value
associated with preserving the effectiveness of ceftriaxone. These issues were outside the scope of the
current trial but may warrant further investigation. A strength of the economic evaluation is that it draws on
prospective data collected during the RCT. Although assumptions were made about treatment strategies
when infection was not cleared, these were based on published clinical guidelines.
There is currently a lack of evidence about how economic evaluations should be undertaken for
interventions addressing AMR.45 Very few economic evaluations have been undertaken that assess
different antibiotic strategies in the context of developing AMR.46,47 The costs associated with AMR in
gonorrhoea require further analysis and there is an urgent need to develop appropriate methods for
economic evaluations of interventions to address AMR in gonorrhoea and other disease areas.48
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FIGURE 16 Incremental cost-effectiveness scatterplot for clearance of infection: gentamicin vs. ceftriaxone.
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Chapter 5 Discussion
The main trial finding is that single-dose gentamicin (240mg) is not shown to be non-inferior to single-doseceftriaxone (500mg) for the treatment of gonorrhoea, when both drugs are combined with a single dose
of oral azithromycin (1 g). The trial was not designed to assess superiority, but the magnitude of the risk
difference (–6.4%, 95% CI –10.4% to –2.4%) and the consistency of the findings on sensitivity analyses
suggest that gentamicin may be less effective than ceftriaxone for the microbiological cure of gonorrhoea.
The difference in efficacy was most marked for pharyngeal gonorrhoea (risk difference –15.3%, 95% CI
–24.0% to –6.5%) and rectal gonorrhoea (risk difference –7.8%, 95% CI –13.6% to –2.0%). For genital
gonorrhoea, gentamicin achieved microbiological cure in 94% of infections compared with a 98%
clearance rate for ceftriaxone (risk difference –4.4%, 95% CI –8.7% to 0.0%).
Both ceftriaxone and gentamicin were generally well tolerated. Nausea was the most commonly reported
side effect of treatment, occurring in 12% of participants receiving ceftriaxone and 14% receiving gentamicin.
Few participants reported vestibulocochlear symptoms; these symptoms, when reported, occurred similarly
between treatment arms: reduction in hearing in 2% of participants receiving ceftriaxone and 1% receiving
gentamicin and dizziness or unsteadiness in 7% (ceftriaxone) and 7% (gentamicin). The proportion of
participants with either clinically important changes in creatinine level from baseline or a creatinine level
exceeding the upper limit of normal was similar in both groups; a high/increased or abnormal creatinine level
was recorded as an AE for only seven participants. All AEs were mild and in three out of the seven cases they
were thought by the local principal investigator (PI) to be related to treatment. The mean change in eGFR
[median (25th percentile, 75th percentile)] was similar in the two treatment groups and not considered of clinical
importance, being –1.3 ml/minute/1.73 m2 [median (–6.7 ml/minute/1.73 m2, 4.3 ml/minute/1.73 m2)] for the
ceftriaxone group and –1.4 ml/minute/1.73 m2 [median (–6.9 ml/minute/1.73 m2, 3.8 ml/minute/1.73 m2)] for
the gentamicin group. Almost all participants receiving either ceftriaxone or gentamicin reported injection site
pain (98% and 99%, respectively) but the severity of the pain was less for ceftriaxone (median VAS score
immediately after injection 15.0) than for gentamicin (median VAS score 31.5). Injection site pain resolved
within a median of 1 hour (IQR 0–12 days) for ceftriaxone and 1.5 hours (IQR 0–24 days) for gentamicin.
A single SAE occurred in a participant who developed severe dizziness 4 days after receiving ceftriaxone.
On subsequent review, he gave a history of eating biscuits containing cannabis shortly before developing
these symptoms.
Efficacy of gentamicin for the treatment of gonorrhoea
The trial was designed to assess the efficacy of gentamicin compared with ceftriaxone and the primary end
point was microbiological cure 14 days after treatment. There are a number of factors that could affect the
response to gentamicin treatment.
Antimicrobial resistance
The mechanisms leading to gentamicin resistance have not been fully elucidated but include reduced uptake
into infected cells as a result of decreased cell membrane permeability to the antibiotic49 or modification of
the drug by cellular enzymes, which reduce its activity.50 For spectinomycin, which is in the same drug class
of aminoglycosides and has a similar mechanism of action, mutations within 16S ribosomal ribonucleic acid
that inhibit binding of the drug to the ribosome have been associated with high-level resistance.51 In vitro
measurement of the MIC for gentamicin in cultured isolates of N. gonorrhoeae provides a phenotypic
assessment of antimicrobial susceptibility, but the ‘breakpoint’ MIC value, below which clinical cure occurs
and above which treatment is ineffective, has not been established. It has been tentatively suggested that an
isolate with a MIC of < 8 mg/l is susceptible, with a MIC of 8–16 mg/l is intermediate and with a MIC of
> 16 mg/l is resistant.29,52 The European Network for STI Surveillance found that 95% of isolates had
gentamicin MICs in the range of 4–8 mg/l,27 using the agar dilution technique. Isolates of N. gonorrhoeae
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from participants in the G-TOG trial had a similar susceptibility profile, with 70% having a MIC of 4–8 mg/l
using the Etest technique.
Previously proposed MIC ‘cut-offs’ points associated with AMR in N. gonorrhoeae for gentamicin,
ceftriaxone and azithromycin are shown in Table 32.
The measurement of MICs requires a positive N. gonorrhoeae culture sample. Participants in the G-TOG
trial had samples taken for culture at their baseline attendance and 2-week follow-up but culture is less
sensitive than NAAT, particularly for extragenital sites, and, therefore, the data on in vitro susceptibility
(using MICs) are limited to the subset of individuals who had a positive culture sample available. For
genital infections, culture isolates were available for 356 out of 402 (88%) NAAT-positive samples at
baseline; for rectal infections, this number was 146 out of 301 (47%) and for pharyngeal infections it was
88 out of 256 (34%).
Caution is, therefore, required in the interpretation of the antibiotic susceptibility profiles, which represent
only a subgroup of the overall trial population, especially for those with pharyngeal and rectal infections.
Overall, the culture-positive and culture-negative groups were similar with respect to age, sex and
ethnicity, although there was a greater proportion of males among those with no culture result available
(94% compared with 79% in the culture-positive group and 78% in the culture-negative group) and there
were fewer white participants (59% compared with 66% and 74% in the culture-positive and culture-
negative groups, respectively).
The extent of tissue penetration of different antimicrobials at the genital, rectal and pharyngeal sites is not
known, nor is the extent of interindividual variation in tissue drug levels. This makes it difficult to interpret
how the MIC values measured in vitro relate to the relative antibiotic susceptibility of gonococcal isolates in
individual trial participants.
There did not appear to be any association between the in vitro gentamicin MIC and response to treatment.
The structurally similar antibiotic spectinomycin has been reported to be less effective for the treatment
of pharyngeal gonorrhoea,55 probably because it fails to achieve bactericidal concentrations within the
infected tissues for a sufficiently long time period to clear infection.5 It is possible that this mechanism is
also relevant for gentamicin.
Participants in both treatment groups received oral azithromycin and treatment failure was associated
with a reduction in in vitro susceptibility (shift of the azithromycin MIC distribution to the right). Overall,
treatment failure occurred in 14 out of 262 (5%) participants who had isolates with an azithromycin MIC
of ≤ 0.5 mg/l compared with 2 out of 12 (17%) participants who had isolates with an azithromycin MIC of
≥ 1 mg/l.
TABLE 32 Minimum inhibitory concentrations associated with AMR in N. gonorrhoeae for gentamicin, ceftriaxone
and azithromycin
Drug
Proposed MIC cut-off points (mg/l)
UK Gonococcal Resistance to
Antimicrobials Surveillance
Programme3
European Committee on
Antimicrobial Susceptibility
Testing53
US Centers for
Disease Control and
Prevention54 Other29,52
Gentamicin – – – > 16
Ceftriaxone > 0.064a > 0.12 > 0.25 –
Azithromycin > 0.5 > 0.5 – –
a Decreased susceptibility.
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In summary, we did not find that gentamicin MICs, as assessed by in vitro antimicrobial susceptibility
testing, accurately predicted treatment failure. This suggests that in vitro laboratory assessment of MICs for
gentamicin is not likely to be helpful in selecting those patients with gonorrhoea who can be successfully
treated with gentamicin.
Reinfection
If a patient is reinfected after treatment, then their follow-up test for gonorrhoea will be positive even after
successful initial therapy. If this occurs following sex with an existing infected partner, then it is likely that
the same subtype of N. gonorrhoeae will be present at baseline and follow-up. If sexual contact was with
a new partner, then the same subtype of N. gonorrhoeae could be present at follow-up (e.g. if this is a
common subtype within the population) or a different subtype may occur.
Sexual contact following treatment for gonorrhoea was well balanced between the treatment groups: it
was reported by 37% (118/322) of participants receiving ceftriaxone [15% (47/322) of whom reported
not using condoms] and 34% (104/302) receiving gentamicin [16% (47/302) of whom reported not using
condoms]. For both groups, a median of two episodes of sexual contact occurred in the interval between
treatment and follow-up. There were similar clearance rates for participants who had and those who had
not had sex following randomisation, and these rates appeared to be similar between treatment groups.
Reinfection of participants with gonorrhoea is, therefore, not likely to explain the difference in treatment
success between participants receiving ceftriaxone and those receiving gentamicin.
Interval between treatment and follow-up assessment
Microbiological cure following treatment was assessed using NAAT and occurred at ≤ 21 days in 81%
of participants in both treatment groups. The median time to assessment of cure did not differ between
the two treatment groups (ceftriaxone 16 days, gentamicin 15 days). The median time to follow-up was
15 days from randomisation for those who were cleared of infection and 15.5 days for those who were
not cleared of infection.
Persistence of bacterial nucleic acid following effective treatment, even in the absence of viable bacteria,
has the potential to cause false-positive test results. Current UK national guidance is to assess cure by
performing a NAAT 2 weeks after treatment, by which time a false-positive result is unlikely.56–60 It has
been suggested that pharyngeal infection may take longer to clear following treatment, with a greater
possibility of a false-positive result 2 weeks after therapy.61 The high treatment success rate at all anatomical
sites in participants receiving ceftriaxone [genital 98% (151/154), pharyngeal 96% (108/113) and rectal
98% (134/137)] suggests that persistence of bacterial nucleic acid (in the absence of viable bacteria)
leading to false-positive results did not occur frequently in the G-TOG trial participants. However, the
pharmacodynamics of gentamicin for the treatment of pharyngeal gonorrhoea are largely unknown and it
remains possible that the rate of bacterial clearance may be slower with gentamicin than with ceftriaxone.
Negative interaction between gentamicin and azithromycin
An antagonistic interaction between gentamicin and azithromycin could potentially reduce the efficacy of
the combination of these two drugs. However, in vitro testing suggests that there is neither antagonism
nor synergy when the two antibiotics are combined;62 furthermore, a recent trial using this combination
demonstrated the potential for a high cure rate using dual therapy, at least in a subset of patients with
genital infection diagnosed by culture.25 An antagonistic interaction between gentamicin and azithromycin
would, therefore, be an unlikely explanation for the difference in cure rates between ceftriaxone and
gentamicin.
Protocol deviations
The proportion of participants reporting protocol deviations was similar between treatment groups and
most deviations were considered to be minor. There was an imbalance in the proportion of participants
who did not receive their randomised medication. However, it was considered unlikely that this was as a
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result of selection bias or knowledge of the treatment allocation. It is therefore believed that the protocol
deviations did not affect the validity of the trial.
Results in context
Two systematic reviews23,24 have reported wide variation in the efficacy of gentamicin for the treatment of
gonorrhoea and highlighted the low quality of the previous studies, which had a significant risk of bias.
A more recent high-quality non-comparative trial evaluated i.m. gentamicin (240 mg) combined with oral
azithromycin (2 g) and reported a cure rate of 100% (lower 95% CI 98.5%).25 The design of this trial is
compared with that of the G-TOG trial in Table 33. An updated literature search (see Appendix 2) was
performed but no further studies evaluating gentamicin for the treatment of gonorrhoea were identified.
There are a number of possible explanations for the higher cure rate reported by Kirkcaldy et al.25 In the
diagnosis of gonorrhoea, culture is less sensitive (≈80%) than NAAT; this is most apparent for pharyngeal
infections (30% sensitivity) and rectal infections (50% sensitivity).63,64 This reduced ability to isolate
extragenital N. gonorrhoeae is likely to be the reason for the small number of pharyngeal and rectal
infections that met the inclusion criteria for the Kirkcaldy et al.25 study.
In the G-TOG trial, we found the efficacy of gentamicin to be higher for genital infections (94%) than for
extragenital infections (pharynx 80% and rectum 90%), which may partially explain the higher overall cure
rate in the Kirkcaldy et al.25 study (100%, 95% CI 98.5% to 100%), in which the majority of infections
were genital.
There is also a theoretical possibility that the lower sensitivity of culture could fail to identify persistent
infection following unsuccessful treatment if transient suppression of N. gonorrhoeae occurred (below the
level detectable by culture) but without cure.
The role of azithromycin in the treatment of gonorrhoea
Participants in the G-TOG trial received dual treatment: 1 g of azithromycin combined with either
ceftriaxone or gentamicin. Azithromycin has previously been shown to be effective for the treatment of
gonorrhoea using a single dose of either 1 g or 2 g,65–68 although these previous studies used culture to
diagnose infection and assess cure, which, as outlined in the previous section, is less sensitive than NAAT.
TABLE 33 Study design for Kirkcaldy et al.25 compared with the G-TOG trial
Design
Study
Kirkcaldy et al.25 G-TOG trial
Number of participants assigned to
gentamicin treatment
309 358
Number of participants receiving gentamicin
who were included in the primary analysis
157 292
Gentamicin dose (mg) 240 240
Azithromycin dose (g) 2 1
Diagnostic criteria Positive culture for
N. gonorrhoeae
Positive NAAT for N. gonorrhoeae or
positive Gram stain on microscopy
Primary end point Negative culture 10–17 days
after treatment
Negative NAAT 14 days after
treatment
Number of participants with pharyngeal
infection receiving gentamicin
10 128
Number of participants with rectal infection
receiving gentamicin
1 147
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Azithromycin resistance and treatment failure has subsequently been reported in a number of geographical
locations.69–73 In the UK, azithromycin-resistant N. gonorrhoeae has been detected intermittently since
2004,74,75 with an ongoing outbreak of high-level azithromycin-resistant isolates identified in England
since 2014.76 The Gonococcal Resistance to Antimicrobials Surveillance Programme reported that 10% of
gonococcal isolates in England and Wales had a MIC of > 0.5 mg/l in 2015, indicating probable resistance.3
In the G-TOG trial, participant treatment failure occurred in 6% of genital infections, 10% of rectal infections
and 20% of pharyngeal infections in those who received gentamicin plus azithromycin, suggesting that oral
azithromycin given as a 1-g dose may be suboptimal, particularly for extragenital gonorrhoea. The large
majority of gonococcal isolates from participants in the G-TOG trial [290/305 (95%)] had azithromycin MICs
within the non-resistant range (≤ 0.5 mg/l). Of the 15 isolates with a MIC of > 0.5 mg/l, two (13%) were
from participants who had treatment failure. The majority of treatment failures overall [14/20 (70%)]
occurred in participants who had isolates with a MIC of ≤ 0.25 mg/l. Sixty participants harboured an isolate
with an azithromycin intermediate MIC of 0.5 mg/l, of whom four (7%) had treatment failure. Thus, we
found in vitro azithromycin resistance was only partially predictive of treatment failure. The limited association
between MIC and treatment efficacy has been reported by others.77,78 It is possible that a higher dose of
azithromycin (2 g), as was used in the Kirkcaldy et al.25 study, would have been more effective, although
without a direct comparative study this is speculative, especially for the treatment of pharyngeal gonorrhoea.
The use of a 1-g dose of azithromycin as monotherapy has also been reported to potentially induce
resistance in N. gonorrhoeae, with a substantial increase in the MIC following treatment.79,80
The use of a 2-g dose of azithromycin combined with gentamicin was associated with a high incidence of
gastrointestinal side effects in the Kirkcaldy et al.25 study, with nausea reported by 26% of participants and
vomiting by 10%. In the G-TOG trial, the 1-g dose was better tolerated: 14% of participants reported nausea
and 4% reported vomiting, which is consistent with previous studies.68 An extended-release formulation of
azithromycin is available that may reduce the incidence of side effects and improve tolerability but there are
limited data directly comparing its AE profile with that of the immediate-release formulation.81,82
The current UK and US gonorrhoea treatment guidelines recommend dual therapy with a regimen
containing oral azithromycin as a 1-g single dose.6 Our findings, which are the first to use the more
sensitive NAATs to assess microbiological clearance, suggest that this component of treatment may be
suboptimal, particularly for extragenital gonococcal infections.
Injection site pain
Participants receiving gentamicin reported more severe injection site pain than those receiving ceftriaxone
(median VAS score 31.5 and 15.0, respectively), with resolution of pain occurring within a median of
1 hour for ceftriaxone and 1.5 hours for gentamicin. The site of injection and the needle gauge were not
prespecified in the trial but would usually be the same for both antibiotics. Ceftriaxone is manufactured as
a powder preparation that is reconstituted with lidocaine, resulting in an injection volume of approximately
2 ml for a 500-mg dose.83 Gentamicin is manufactured as a solution: a 240-mg dose equates to an
injection volume of 6 ml.84 It is likely that this larger volume of injection led to participants who received
gentamicin reporting more severe local site pain. In addition, the local anaesthetic effect of lidocaine in
those receiving ceftriaxone is likely to have reduced the discomfort following injection.
Safety
Ceftriaxone and gentamicin were generally well tolerated; with a similar proportion of AEs reported in
both treatment arms. Gastrointestinal side effects were the most commonly reported: nausea was reported
by 12% (38/320) of those who received ceftriaxone and 14% (41/298) of those who received gentamicin.
The majority of these side effects were classified as grade 1 (able to eat normally), with only 2% in each
treatment group (ceftriaxone 8/320, gentamicin 5/298) being classified as grade 2 (oral intake significantly
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decreased). There were no grade 3 events (no significant oral intake or requiring intravenous fluids) and
nausea resolved within a median of 3 hours following treatment in both treatment groups. Vomiting was
reported by 1% (3/320) of those who received ceftriaxone and 4% (12/298) of those who received gentamicin.
Ceftriaxone and gentamicin are licensed medications that have well-recognised safety profiles. Nausea and
vomiting are uncommon side effects of ceftriaxone (range of incidence rate: ≥ 1/1000 to < 1/100)83 and
have been reported in association with gentamicin,84 but are common following the use of oral azithromycin
(≥ 1/100 to < 1/10).85 It is, therefore, probable that the gastrointestinal side effects reported were principally
caused by azithromycin, although the higher reported rate of vomiting in those receiving gentamicin (4%,
compared with 1% for ceftriaxone) suggests that gentamicin may also have been a contributing factor.
Dizziness or unsteadiness was reported in 7% of participants who received their allocated treatment
(ceftriaxone 24/302, gentamicin 21/298) but was classified as grade 1 (not interfering with function) in the
large majority (ceftriaxone 20/24, gentamicin 19/21). One participant who received ceftriaxone reported
grade 4 dizziness (bedridden or disabled).
Dizziness is uncommon (≥ 1/1000 to < 1/100) following treatment with azithromycin or ceftriaxone.83,85
Gentamicin is potentially vestibulotoxic;86 it can cause damage to the vestibular apparatus, initially affecting
the cristae and progressing to the striolar regions of the maculae,87 and can cause dizziness, ataxia and
nystagmus. Most gentamicin studies have used a prolonged course of treatment and the safety of a single
dose is less well characterised, but a recent systematic review of single-dose therapy found vestibulotoxicity
to be rare,88 which is consistent with the G-TOG trial findings.
Gentamicin can also cause renal impairment following reuptake of the drug in the proximal renal tubule,
where it leads to a locally high renal drug concentration.89 The recent review of AEs of gentamicin reported
that a transient rise in creatinine was common following a single dose of gentamicin, although many of the
relevant studies were in elderly, surgical patients, which may not be directly applicable to the G-TOG trial
population.88 In the G-TOG trial participants, we found a median change in eGFR that was similar in both
treatment groups [ceftriaxone –1.3 ml/minute/1.73 m2 (IQR –6.7–4.3 ml/minute/1.73 m2), gentamicin
–1.4 ml/minute/1.73 m2 (IQR –6.9–3.8 ml/minute/1.73 m2)]. This magnitude of change is not considered to
be of clinical importance. A small number of participants (2%) experienced a change of > 30% in creatinine
level following treatment but, despite this, remained within or just above the upper limit of normal.
The results of the trial were presented to the PPI representatives and their feedback was sought. They
considered the study results to be reassuring regarding the safety of gentamicin and that using gentamicin
as a second-line therapy in those unable to receive ceftriaxone would be acceptable.
Strengths and limitations
The G-TOG trial was delivered through a registered clinical trials unit and had a robust design resulting in
well-balanced treatment arms and a low risk of bias. The trial was pragmatic in design and likely to be
relevant to clinical practice in the UK and other countries with similar health-care systems. It included
symptomatic and asymptomatic patients, patients with a wide age range, HIV-positive and HIV-negative
individuals, men and women, heterosexual men and MSM and a wide variety of ethnic groups, which
provides generalisability for our findings. Recruitment was completed to time and target and the sample
size was large enough to provide a clear result.
The potential for treatment unblinding was low. It is possible that a participant who had previously
received treatment with ceftriaxone (41% of participants were known to have had at least one previous
episode of gonorrhoea) may have recognised their therapy and that this could have affected the reporting
of subjective outcomes. However, both treatments were given by injection and we would consider it
unlikely that participants distinguished between treatments based on their preparation or administration.
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The reporting of side effects was similar in both treatment arms. We were not aware of any clinicians
being unblinded.
The trial design allowed for a loss to follow-up of ≤ 10% of participants (90% of participants were to be
available for analysis) but data were available for analysis of the primary end point in only 85% (306/362)
of participants allocated to ceftriaxone and 82% (292/358) of those allocated to gentamicin. The sample
size for the trial had been calculated to provide 90% power and it was felt that, despite fewer participants
having data for the primary outcome measure, the result was robust as all sensitivity analyses were
supportive. The G-TOG trial was designed and powered as a non-inferiority trial, which prevents us making
a firm conclusion about the superiority of ceftriaxone, but the size of the risk difference and consistency of
our findings in secondary sensitivity analyses suggest that it is likely that gentamicin is less effective than
ceftriaxone. The pre-trial estimate of 10% for loss to follow-up was based on a patient return rate of
80–85% in routine clinical practice, with an expectation that with closer monitoring, visit reminders and a
monetary incentive this could be increased to 90%. Our experience suggests that during trial design
greater allowance should have been made for incorrect sampling at follow-up when estimating the
number of patients with available primary end-point data.
The main factor limiting recruitment was research capacity within sexual health centres, for example
availability of research nurses and experienced PIs, which was exacerbated by widespread structural reform
in the clinical service that occurred during the time of the G-TOG trial. This resulted in some centres not
meeting their pre-trial estimates for recruitment. The trial has demonstrated a need to improve engagement
in research and increase research expertise in the area of sexual health.
Unexpectedly, a number of participants who were recruited to the trial were found to have a negative AC2
NAAT at their baseline visit [ceftriaxone arm 12% (45/362); gentamicin arm 12% (42/358)]. These were all
individuals who had been previously tested and found to be positive on NAAT, but who had not yet
received treatment and had been recalled to the clinic to be given antibiotic therapy. In normal clinical
practice, a repeat NAAT would not be performed before treatment if a previous test result was positive.
The apparently spontaneous reversion from positive to negative NAAT observed in some trial participants
could result from one of the following:
l An initial false-positive NAAT before trial entry. NAAT for N. gonorrhoeae has a high specificity,
particularly for genital specimens, which makes this unlikely.90
l A false-negative NAAT at the baseline trial visit. NAAT for N. gonorrhoeae has a high sensitivity, which
makes this also unlikely.90
l Natural clearance of gonorrhoea without antibiotic therapy. It is not known how often this occurs
because it would be unethical to knowingly leave gonorrhoea untreated and, as noted above, repeat
testing following a positive test result before treatment is not routine practice. In one natural history
study, none of 16 women with gonorrhoea had spontaneous clearance over a 5- to 11-week period.91
In contrast, van Liere et al.92 reported natural clearance of 20% (5/25) of gonococcal infections in a
median interval of 11 days between initial testing and returning for follow-up.
The occurrence of 12% of participants with negative tests at their baseline visit does not bias our results
since they were equally distributed between the treatment arms. A lack of bias is also supported by the
secondary sensitivity analysis that excluded these participants and that was consistent in demonstrating
that gentamicin was not non-inferior to ceftriaxone (risk difference –7.1%, 95% CI –11.4% to –2.8%).
The efficacy of antibiotic therapy for gonorrhoea varies over time as different resistant subtypes of infection
develop and circulate within a population. Our findings are therefore applicable only to the UK or similar
settings at the present time; any future interpretation will need to account for changes in antimicrobial
susceptibility. For example, if high-level resistance to ceftriaxone subsequently develops, resulting in a high
rate of treatment failure, then gentamicin may become appropriate first-line therapy. Equally, if future
circulating subtypes of gonorrhoea become highly resistant to gentamicin, its use would be inappropriate.
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Chapter 6 Conclusions
The G-TOG trial compared single-dose gentamicin (240 mg) with single-dose ceftriaxone (500 mg) forthe treatment of gonorrhoea and found that non-inferiority of gentamicin to ceftriaxone could not be
demonstrated. Gentamicin led to microbiological cure in 94% of participants with genital infection,
suggesting that its use would be appropriate as second-line therapy, but cure rates were lower for infections
in the rectum (90% cure rate) and pharynx (80% cure rate). Single-dose gentamicin was well tolerated.
Implications for health care
The G-TOG trial has clearly demonstrated that gentamicin cannot be considered to be non-inferior to
ceftriaxone, with the largest risk differences in cure being observed in patients with extragenital gonorrhoea.
It is, therefore, probable that clinicians will wish to continue to use ceftriaxone (plus azithromycin) as their
preferred first-line therapy. However, gentamicin (plus azithromycin) achieved a cure rate of 94% for genital
gonorrhoea and its use in patients who are allergic, intolerant or resistant to ceftriaxone would be acceptable.
The lower cure rates for rectal (90%) and pharyngeal (80%) infections make gentamicin a less attractive
treatment option, but antibiotics are generally less effective at these sites and gentamicin may still be useful
as a second- or third-line therapy. A repeat test for gonorrhoea to ensure microbiological cure would be
advisable following gentamicin therapy.
The lack of correlation between gentamicin MIC values, obtained on in vitro sensitivity testing, and
microbiological cure suggests that these should be interpreted with caution and that they have limited
predictive value in clinical practice. There were too few failures with ceftriaxone to comment on any
association with in vitro MIC testing. For azithromycin, there was an association between treatment failure
and in vitro MICs but it was relatively weak, which limits its utility in clinical practice.
A clinically significant proportion of participants in the gentamicin treatment arm failed therapy, despite
also receiving 1 g of oral azithromycin; this suggests that, independent of the efficacy of gentamicin,
azithromycin at this dose may be suboptimal, especially for extragenital gonorrhoea. Although the number
of culture isolates was limited, a modest trend towards a higher azithromycin MIC in this group suggests
that a higher dose of azithromycin (e.g. 2 g) might be more effective but with the caveat that the tolerability
of this dose is poor as a result of gastrointestinal side effects. Azithromycin is currently used to reduce the
development of resistance and ‘protect’ ceftriaxone by providing microbiological cover if cephalosporin
resistance develops. The observation in the G-TOG trial that a 1-g dose of azithromycin, even in combination
with gentamicin, has a significant failure rate raises concerns about the effectiveness of this approach.
The results of the economic evaluation demonstrate that gentamicin is likely to be more costly than
ceftriaxone in the treatment of gonorrhoea. This means that there is no evidence that gentamicin is
non-inferior to ceftriaxone in the treatment of gonorrhoea, nor is there evidence that it is cost neutral.
However, the economic analysis was necessarily restricted because it was not possible to fully take into
account the potential costs associated with AMR in gonorrhoea, nor the potential value associated with
preserving the effectiveness of ceftriaxone.
A single dose of 240 mg of gentamicin was found to cause few AEs and had a safety profile comparable
to that of ceftriaxone. In particular, there was no increase in the frequency of vestibulocochlear or renal
side effects, which have been associated with prolonged courses of gentamicin. This provides reassurance
for the safe use of gentamicin in clinical practice. Participants receiving i.m. gentamicin reported more
injection site pain than those receiving ceftriaxone, most probably related to the larger volume of injection.
The pain resolved fully within a few hours for the majority of individuals but an alternative would be to
give two separate 3-ml injections of gentamicin intramuscularly into each buttock rather than a single 6-ml
injection, although PPI input during trial design suggested that a single injection might be preferred.
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Recommendations for research
The lack of a strong association between the in vitro assessment of gonococcal resistance to gentamicin
and clinical response highlights a need to explore further why gentamicin treatment is not effective in
some patients and whether or not its efficacy can predicted. Whole-genome sequencing will allow the
identification of specific subtypes of N. gonorrhoeae, which may provide insights into the mechanisms of
resistance and detect potential markers of resistance.
Antibiotic resistance in N. gonorrhoeae is common and treatment options remain limited. The development
of a preventative or therapeutic vaccine is therefore a priority and greater understanding of the immune
response to infection is required to facilitate this. The collection and storage of before-and-after serum
samples, and matched NAAT and culture samples in the G-TOG trial, will facilitate this future work.
The role of multiple different gonococcal infections within a single individual in the transmission of resistance
is poorly understood. Transfer of resistance genes between N. gonorrhoeae is common and the archive of
isolates collected in the G-TOG trial will allow an exploration of how frequently multiple infections occur and
their potential role in the spread of resistance.
Azithromycin used as a 1-g dose to treat gonorrhoea was associated with a significant treatment failure
rate, suggesting that it is not the optimal antibiotic to use as part of dual therapy designed to slow the
spread of resistance. Further studies are required to evaluate alternative ‘second agents’, including a
2-g dose of azithromycin using an extended spectrum formulation that might improve tolerability.
Further research is needed to evaluate the potential costs associated with AMR in gonorrhoea. In addition,
there needs to be further development of appropriate methods for economic evaluations when AMR is
likely to be an issue. Such work will benefit from case studies, and examining the wider implications
associated with alternative treatments for gonorrhoea would provide a valuable exemplar to aid in the
development of general approaches.
CONCLUSIONS
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Appendix 1 Summary of trial amendments
Amendment reference
and date Amendment details
Previous version number
and date
New version number and
date
Substantial amendment
06, 18 June 2015
Removal of PK substudy
and amendment to
eligibility criteria
1.0, 27 May 2014 2.0, 17 June 2015
PIS 1.0, 4 July 2014 2.0, 4 June 2015
Informed consent form 1.0, 27 May 2014 2.0, 4 June 2015
Substantial amendment
08, 22 October 2015
Change of RSI 80 mg of cidomycin or a 2-ml
solution for injection (date of
revision of text: 19 June 2013)
80 mg of cidomycin or a 2-ml
solution for injection (date of
revision of text: 29 June 2015)
Substantial amendment
09, 21 December 2015
Amendment to PIS to
clarify sending of AC2
NAAT swabs to STBRUa
2.0, 4 June 2015 3.0, 21 December 2015
PK, pharmacokinetics; RSI, Reference Safety Information; STBRU, Sexually Transmitted Bacteria Reference Unit.
a Owing to STBRU closure during the trial, swabs were analysed by PHE.
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Appendix 2 Search strategy for studies assessing
the treatment of gonorrhoea with gentamicin
MEDLINE and EMBASE
Date range searched: 1 March 2013 to 22 April 2017.
Date searched: 22 April 2017
One hundred and fifty-six references identified and reviewed
Search strategy
1. gonorrhoea.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
2. gonorrhea.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
3. Neisseria gonorrhoeae.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
4. N gonorrhoeae.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
5. 1 or 2 or 3 or 4
6. gentamicin.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
7. gentamycin.mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]
8. 6 or 7
9. 5 and 8
10. limit 9 to yr =‘2013-Current’
11. remove duplicates from 10
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Appendix 3 Additional tables, listings and figures
TABLE 34 Genital clearance of N. gonorrhoeae, by sex
Clearance
Sex, n (%)
Male Female
Ceftriaxone Gentamicin Ceftriaxone Gentamicin
Number with infection at genital site 107 142 47 32
Cleared of N. gonorrhoeae 106 (99) 132 (93) 45 (96) 31 (97)
Not cleared of N. gonorrhoeae 1 (1) 10 (7) 2 (4) 1 (3)
TABLE 35 Summary of symptom resolution
Symptom
Treatment group, n (%)
Ceftriaxone (N= 362) Gentamicin (N= 358)
Symptom present at baseline Symptom present at baseline
No Yes Not known No Yes Not known
Genital discharge at 2 weeks
No 191 (53) 122 (34) 0 (0) 154 (43) 139 (39) 0 (0)
Yes 1 (< 0.5) 7 (2) 0 (0) 1 (< 0.5) 8 (2) 0 (0)
Not known 17 (5) 24 (7) 0 (0) 24 (7) 32 (9) 0 (0)
Dysuria at 2 weeks
No 214 (59) 104 (29) 0 (0) 174 (49) 116 (32) 0 (0)
Yes 1 (< 0.5) 2 (1) 0 (0) 0 (0) 12 (3) 0 (0)
Not known 22 (6) 19 (5) 0 (0) 30 (8) 26 (7) 0 (0)
Anorectal pain at 2 weeks
No 306 (85) 12 (3) 0 (0) 294 (82) 5 (1) 0 (0)
Yes 2 (1) 1 (< 0.5) 0 (0) 1 (< 0.5) 2 (1) 0 (0)
Not known 39 (11) 2 (1) 0 (0) 55 (15) 1 (< 0.5) 0 (0)
Rectal discharge at 2 weeks
No 308 (85) 11 (3) 0 (0) 294 (82) 6 (2) 0 (0)
Yes 1 (< 0.5) 1 (< 0.5) 0 (0) 0 (0) 2 (1) 0 (0)
Not known 41 (11) 0 (0) 0 (0) 54 (15) 2 (1) 0 (0)
Sore throat at 2 weeks
No 269 (74) 42 (12) 0 (0) 253 (71) 42 (12) 0 (0)
Yes 5 (2) 5 (1) 0 (0) 4 (1) 3 (1) 0 (0)
Not known 35 (10) 6 (2) 0 (0) 49 (14) 7 (2) 0 (0)
continued
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TABLE 35 Summary of symptom resolution (continued )
Symptom
Treatment group, n (%)
Ceftriaxone (N= 362) Gentamicin (N= 358)
Symptom present at baseline Symptom present at baseline
No Yes Not known No Yes Not known
Rectal bleeding at 2 weeks
No 310 (86) 7 (2) 0 (0) 294 (82) 7 (2) 0 (0)
Yes 3 (1) 1 (< 0.5) 0 (0) 1 (< 0.5) 0 (0) 0 (0)
Not known 40 (11) 1 (< 0.5) 0 (0) 55 (15) 1 (< 0.5) 0 (0)
Tenesmus at 2 weeks
No 313 (86) 7 (2) 0 (0) 298 (83) 3 (1) 0 (0)
Yes 0 (0) 1 (< 0.5) 0 (0) 1 (< 0.5) 0 (0) 0 (0)
Not known 41 (11) 0 (0) 0 (0) 55 (15) 1 (< 0.5) 0 (0)
Constipation at 2 weeks
No 302 (83) 10 (3) 0 (0) 293 (82) 3 (1) 0 (0)
Yes 8 (2) 1 (< 0.5) 0 (0) 5 (1) 1 (< 0.5) 0 (0)
Not known 41 (11) 0 (0) 0 (0) 56 (16) 0 (0) 0 (0)
Intermenstrual bleeding at 2 weeks
No 53 (15) 8 (2) 1 (< 0.5) 41 (11) 5 (1) 0 (0)
Yes 2 (1) 1 (< 0.5) 0 (0) 2 (1) 0 (0) 0 (0)
Not known 4 (1) 0 (0) 0 (0) 15 (4) 2 (1) 0 (0)
Post-coital bleeding at 2 weeks
No 58 (16) 5 (1) 0 (0) 40 (11) 5 (1) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 6 (2) 0 (0) 0 (0) 18 (5) 2 (1) 0 (0)
TABLE 36 Summary of symptom resolution for females
Symptom
Treatment group, n (%)
Ceftriaxone (N= 69) Gentamicin (N= 65)
Symptom present at baseline Symptom present at baseline
No Yes Not known No Yes Not known
Genital discharge at 2 weeks
No 35 (51) 24 (35) 0 (0) 30 (46) 15 (23) 0 (0)
Yes 1 (1) 5 (7) 0 (0) 1 (2) 4 (6) 0 (0)
Not known 3 (4) 1 (1) 0 (0) 8 (12) 7 (11) 0 (0)
Dysuria at 2 weeks
No 45 (65) 20 (29) 0 (0) 42 (65) 6 (9) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 2 (3) 0 (0)
Not known 3 (4) 1 (1) 0 (0) 11 (17) 4 (6) 0 (0)
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TABLE 36 Summary of symptom resolution for females (continued )
Symptom
Treatment group, n (%)
Ceftriaxone (N= 69) Gentamicin (N= 65)
Symptom present at baseline Symptom present at baseline
No Yes Not known No Yes Not known
Anorectal pain at 2 weeks
No 63 (91) 1 (1) 0 (0) 48 (74) 2 (3) 0 (0)
Yes 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 0 (0) 0 (0)
Rectal discharge at 2 weeks
No 64 (93) 1 (1) 0 (0) 49 (75) 1 (2) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 0 (0) 0 (0)
Sore throat at 2 weeks
No 56 (81) 8 (12) 0 (0) 41 (63) 9 (14) 0 (0)
Yes 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 12 (18) 3 (5) 0 (0)
Rectal bleeding at 2 weeks
No 63 (91) 2 (3) 0 (0) 50 (77) 0 (0) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 0 (0) 0 (0)
Tenesmus at 2 weeks
No 64 (93) 1 (1) 0 (0) 49 (75) 0 (0) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 0 (0) 0 (0)
Constipation at 2 weeks
No 58 (84) 4 (6) 0 (0) 48 (74) 0 (0) 0 (0)
Yes 3 (4) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 0 (0) 0 (0)
Intermenstrual bleeding at 2 weeks
No 53 (77) 8 (12) 1 (1) 41 (63) 5 (8) 0 (0)
Yes 2 (3) 1 (1) 0 (0) 2 (3) 0 (0) 0 (0)
Not known 4 (6) 0 (0) 0 (0) 15 (23) 2 (3) 0 (0)
Post-coital bleeding at 2 weeks
No 58 (84) 5 (7) 0 (0) 40 (62) 5 (8) 0 (0)
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Not known 6 (9) 0 (0) 0 (0) 18 (28) 2 (3) 0 (0)
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TABLE 37 Summary of symptom resolution for males
Symptom
Treatment group, n (%)
Ceftriaxone (N= 293) Gentamicin (N= 292)
Symptom present at baseline Symptom present at baseline
No Yes No Yes
Genital discharge at 2 weeks
No 156 (53) 98 (33) 123 (42) 124 (42)
Yes 0 (0) 2 (1) 0 (0) 4 (1)
Not known 14 (5) 23 (8) 16 (5) 25 (9)
Dysuria at 2 weeks
No 169 (58) 84 (29) 131 (45) 110 (38)
Yes 1 (< 0.5) 2 (1) 0 (0) 10 (3)
Not known 19 (6) 18 (6) 19 (7) 22 (8)
Anorectal pain at 2 weeks
No 243 (83) 11 (4) 245 (84) 3 (1)
Yes 1 (< 0.5) 1 (< 0.5) 1 (< 0.5) 2 (1)
Not known 35 (12) 2 (1) 40 (14) 1 (< 0.5)
Rectal discharge at 2 weeks
No 244 (83) 10 (3) 244 (84) 5 (2)
Yes 1 (< 0.5) 1 (< 0.5) 0 (0) 2 (1)
Not known 37 (13) 0 (0) 39 (13) 2 (1)
Sore throat at 2 weeks
No 213 (73) 34 (12) 211 (72) 33 (11)
Yes 4 (1) 5 (2) 4 (1) 3 (1)
Not known 31 (11) 6 (2) 37 (13) 4 (1)
Rectal bleeding at 2 weeks
No 247 (84) 5 (2) 243 (83) 7 (2)
Yes 3 (1) 1 (< 0.5) 1 (< 0.5) 0 (0)
Not known 36 (12) 1 (< 0.5) 40 (14) 1 (< 0.5)
Tenesmus at 2 weeks
No 249 (85) 6 (2) 248 (85) 3 (1)
Yes 0 (0) 1 (< 0.5) 0 (0) 0 (0)
Not known 37 (13) 0 (0) 40 (14) 1 (< 0.5)
Constipation at 2 weeks
No 244 (83) 6 (2) 244 (84) 3 (1)
Yes 5 (1) 1 (< 0.5) 4 (1) 0 (0)
Not known 37 (13) 0 (0) 41 (14) 0 (0)
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TABLE 38 Baseline data by treatment arm and availability of primary outcome
Characteristic
Treatment group
Ceftriaxone Gentamicin
Without
clearance data
(N= 56)
With clearance
data (N= 306)
Without
clearance data
(N= 66)
With clearance
data (N= 292)
Age at randomisation (years)
Mean (SD) 28.6 (8.9) 30.5 (10.3) 27.8 (8.7) 31.1 (10.1)
Median (25th percentile, 75th percentile) 26.2 (22.2, 32.1) 27.7 (22.7, 35.2) 25.8 (21.7, 31.6) 29 (23.2, 35.9)
Minimum, maximum 18.7, 57.4 16.1, 70.2 16.5, 51.1 17.1, 68.4
Sex, n (%)
Male 50 (89) 243 (79) 47 (71) 245 (84)
Female 6 (11) 63 (21) 19 (29) 46 (16)
Other 0 (0) 0 (0) 0 (0) 1 (< 0.5)
Ethnicity, n (%)
White 34 (61) 207 (68) 47 (71) 208 (71)
Black 11 (20) 42 (14) 9 (14) 39 (13)
Asian 5 (9) 21 (7) 3 (5) 15 (5)
Mixed race 4 (7) 23 (8) 7 (11) 19 (7)
Other 2 (4) 13 (4) 0 (0) 11 (4)
Country of birth, n (%)
UK 38 (68) 220 (72) 51 (77) 202 (69)
Other 18 (32) 86 (28) 15 (23) 90 (31)
If other, region
Europe (non-UK) 4 (7) 14 (5) 4 (6) 10 (3)
North America 1 (2) 17 (6) 3 (5) 11 (4)
Asia Pacific 8 (14) 43 (14) 5 (8) 51 (17)
Latin America 1 (2) 6 (2) 1 (2) 10 (3)
Middle East 1 (2) 1 (< 0.5) 1 (2) 4 (1)
Africa 3 (5) 5 (2) 1 (2) 4 (1)
Creatinine level (µmol/l)
Mean (SD) 78.6 (18) 78.6 (14.9) 74.2 (13) 79.1 (16.2)
Median (25th percentile, 75th percentile) 76 (67, 87) 78 (69, 88) 72 (63.5, 84) 77 (69, 87)
Minimum, maximum 42, 124 45, 137 51, 104 26, 154
n 51 292 52 280
Medical history, n (%)
Diabetes mellitus 0 (0) 3 (1) 0 (0) 1 (< 0.5)
Otitis media 0 (0) 9 (3) 1 (2) 6 (2)
Renal disease 0 (0) 3 (1) 1 (2) 3 (1)
Liver disease 1 (2) 7 (2) 2 (3) 3 (1)
Immunodeficiency 5 (9) 29 (9) 2 (3) 22 (8)
Any known drug allergies 2 (4) 15 (5) 7 (11) 18 (6)
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TABLE 38 Baseline data by treatment arm and availability of primary outcome (continued )
Characteristic
Treatment group
Ceftriaxone Gentamicin
Without
clearance data
(N= 56)
With clearance
data (N= 306)
Without
clearance data
(N= 66)
With clearance
data (N= 292)
Participants with infection at each site, n (%)
Genital 36 (64) 154 (50) 45 (68) 174 (60)
Pharyngeal 15 (27) 113 (37) 26 (39) 102 (35)
Rectal 22 (39) 137 (45) 28 (42) 119 (41)
SD, standard deviation.
TABLE 39 Adverse events
Description Severity Outcome Treatment group
Pain radiating down left leg since injection. Difficulty
standing
Moderate Recovered/resolved Ceftriaxone
Folliculitis Mild Recovered/resolved Ceftriaxone
Very strong stomach ache Mild Recovered/resolved Ceftriaxone
Ear pain Mild Unknown Ceftriaxone
Right inner ear pain Mild Recovered/resolved Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Dyspepsia Mild Ongoing Ceftriaxone
Occasional diarrhoea Mild Ongoing Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Cold/flu-like symptoms Mild Ongoing Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Diarrhoea Moderate Ongoing Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Tinitus Mild Recovered/resolved Ceftriaxone
Creatinine level increased from 87 µmol/l in v1 on
15 January 2016 to 123 µmol/l in v2 on 3 February 2016
Mild Ongoing Ceftriaxone
Vulval thrush (candida) Mild Ongoing Ceftriaxone
Loose stools Mild Recovered/resolved Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Diarrhoea Mild Recovered/resolved Ceftriaxone
Grade 4 dizziness Severe Recovered/resolved Ceftriaxone
Felt like been kicked by a horse Mild Recovered/resolved Ceftriaxone
Bell’s palsy Mild Ongoing Ceftriaxone
Tonsillitis Mild Recovered/resolved Ceftriaxone
Discomfort in left upper abdomen Mild Recovered/resolved Ceftriaxone
Lethargy Moderate Recovered/resolved Ceftriaxone
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TABLE 39 Adverse events (continued )
Description Severity Outcome Treatment group
Nausea Mild Recovered/resolved Ceftriaxone
Running nose for 2 days Mild Recovered/resolved Ceftriaxone
Fatigue Moderate Ongoing Ceftriaxone
Chesty cough Moderate Ongoing Ceftriaxone
Fatigue Mild Recovered/resolved Ceftriaxone
Cellulitis Mild Ongoing Ceftriaxone
Skin itch and bumps Moderate Ongoing Ceftriaxone
Septic tonsillitis Moderate Recovered/resolved Ceftriaxone
Pregnancy at visit 2 Mild Recovered/resolved Ceftriaxone
High creatinine level Mild Ongoing Ceftriaxone
Migraine Mild Ongoing Ceftriaxone
Diarrhoea Mild Ongoing Ceftriaxone
Toothache Mild Ongoing Ceftriaxone
Rectal bleeding Mild Recovered/resolved Ceftriaxone
Right lower-leg cellulitis Moderate Ongoing Ceftriaxone
Diarrhoea Mild Recovered/resolved Ceftriaxone
Aching back Mild Ongoing Ceftriaxone
Aching neck Mild Ongoing Ceftriaxone
Bleeding on wiping post-BO (perianal warts) Mild Ongoing Ceftriaxone
Fever (39.6 °C) Mild Recovered/resolved Ceftriaxone
Loose stool Mild Recovered/resolved Ceftriaxone
Increased anxiety Mild Recovered/resolved Ceftriaxone
Flu-like symptoms Mild Recovered/resolved Ceftriaxone
Sore throat Mild Recovered/resolved Ceftriaxone
Headache Mild Recovered/resolved Ceftriaxone
Creatinine level increased from 76 to 124mg/dl Mild Recovered/resolved Ceftriaxone
Raised creatinine level Mild Recovered/resolved Ceftriaxone
Anorectal pain Mild Recovered/resolved Ceftriaxone
Deranged creatinine level Mild Ongoing Ceftriaxone
Diarrhoea Mild Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Cold symptoms Mild Ongoing Gentamicin
Abdominal pain Mild Recovered/resolved Gentamicin
Lethargy Mild Recovered/resolved Gentamicin
Mouth ulcers Mild Ongoing Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
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TABLE 39 Adverse events (continued )
Description Severity Outcome Treatment group
Headache Moderate Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Bloated Mild Recovered/resolved Gentamicin
Diarrhoea Severe Recovered/resolved Gentamicin
Viral URTI Mild Ongoing Gentamicin
Visit 2 bloods: hyperkalaemia (potassium level 6.1).
Rpt= 5.1. Likely to be artefactual
Moderate Recovered/resolved Gentamicin
Nausea Mild Recovered/resolved Gentamicin
Dizziness Mild Recovered/resolved Gentamicin
Nausea Mild Recovered/resolved Gentamicin
Rash Mild Ongoing Gentamicin
Sore throat Mild Ongoing Gentamicin
Raised creatinine level at visit 2: 106 umol/l (grade: mild) Mild Ongoing Gentamicin
Raised potassium level result at visit 1: 5.6 mmol/l Mild Recovered/resolved Gentamicin
Rectal itching Mild Recovered/resolved Gentamicin
Stomach cramps Mild Recovered/resolved Gentamicin
Heartburn Mild Recovered/resolved Gentamicin
Pain at injection site (buttock) Mild Ongoing Gentamicin
Sickness Severe Recovered/resolved Gentamicin
Pain at site of injection Mild Ongoing Gentamicin
Raised creatinine level Mild Ongoing Gentamicin
Left eye conjunctivitis Mild Unknown Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Diarrhoea Mild Ongoing Gentamicin
Tonsillitis Moderate Recovered/resolved Gentamicin
URTI Moderate Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Stiff arms Moderate Ongoing Gentamicin
Diarrhoea (one episode, type 6, no blood or mucous) Mild Recovered/resolved Gentamicin
Diarrhoea (one episode, type 7, no blood or mucous) Mild Recovered/resolved Gentamicin
Myalgia Mild Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Diarrhoea Mild Recovered/resolved Gentamicin
Bilateral flank pain – intermittent/stabbing Mild Recovered/resolved Gentamicin
Back pain Moderate Recovered/resolved Gentamicin
BO, bowel opening; URTI, upper respiratory tract infection.
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TABLE 40 Concomitant medications
Drug name Treatment group
Ceftriaxone, 500 mg stat Gentamicin
Azithromycin, 1 g stat p.o. Ceftriaxone
Azithromycin, 1 g p.o. Ceftriaxone
Doxycycline Ceftriaxone
Doxycycline Ceftriaxone
Doxycycline Gentamicin
Trimethoprim Gentamicin
Ceftriaxone Gentamicin
Doxycycline Gentamicin
Doxycycline Gentamicin
Doxycycline, 100 mg Ceftriaxone
Metronidazole Gentamicin
Ceftriazone Gentamicin
Clarithromycin Ceftriaxone
Doxycycline Ceftriaxone
Doxycycline Ceftriaxone
Ofloxacin Gentamicin
Doxycycline Ceftriaxone
Doxycycline Gentamicin
Doxycycline, 100 mg b.i.d. Gentamicin
Doxycycline Gentamicin
Doxycycline Gentamicin
Doxycycline Ceftriaxone
Doxycycline Ceftriaxone
Doxycycline Gentamicin
Metronidazole, 400-mg tablet Ceftriaxone
Azithromycin Gentamicin
Doxycycline Gentamicin
Doxycycline Ceftriaxone
b.i.d., bis in die (twice a day); p.o., per os (by mouth); stat, statim.
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TABLE 41 Protocol deviations recorded on the protocol deviation log
Details Treatment group
Participant is heterosexual and a rectal swab was taken and there were no indications to take this Gentamicin
Participant is heterosexual & a pharyngael swab was taken and there were no indications to take this Gentamicin
wrong blood test requested = no creatinine done on pt Ceftriaxone
No microscopy done on FU- NAAT and cultures taken only which were negative Ceftriaxone
Creatinine not done as wrong test requested on form- too late to add on as blood destroyed after 7d Ceftriaxone
Patient did not have full examiniation done at FU as was only oral GC pos Gentamicin
Clinical examination not done at FU appt as patient asymptomatic needed for all patients though Ceftriaxone
Examination not performed on Follow Up Visit Ceftriaxone
Rectal GC culture not obtained on Visit 2 Ceftriaxone
Pt allergic to penicillin wrongly randomized Ceftriaxone
Pt withdrawn due to change of clinicians decision. Pt treated for PID Gentamicin
All tests on V1 obtained as per protocol partly discarded as Pt could not continue the study Gentamicin
Pt randomized into the trial before microscopy results available – not eligible due to BV infection Ceftriaxone
Creatinine test not performed by LAB CK done instead. Called the Lab the samples already destroyed Gentamicin
Creatinine blood test not performed by Lab CK test done instead-contacting the Lab-sample
destroyed
Ceftriaxone
oral NAAT & culture tests obtained on Visit 2 – while not required Gentamicin
participant declined clinical examination at follow-up Gentamicin
Creatinin result unavailable due to unlabled specimen Ceftriaxone
Dose Administration Details not entered on Randomisation system by the injecting nurse Ceftriaxone
isolate not saved Gentamicin
VAS not done at baseline Ceftriaxone
test result of recal culture not obtainable from lab Gentamicin
test result of pharyngeal culture not obtainable from lab Gentamicin
isolate not saved Ceftriaxone
isolate not saved Ceftriaxone
Pt declined urethral GC culture test on FU visit Ceftriaxone
Gc not isolated Ceftriaxone
Incorrect labelling of sample Ceftriaxone
Oral NAAT not repeated on visit 2 Gentamicin
Oral Culture not taken on 2nd visit Gentamicin
no creatinine results sample request lost in transit Ceftriaxone
Patient declined rectal swab as no risk of infection he percieved Gentamicin
Visit 2 culture sample not taken Ceftriaxone
Creatine result unavailable sample not recieved by QEHB lab Ceftriaxone
Study team aware pregnancy test not taken before randomisation. Patient given treatment when
pregna[nt]
Gentamicin
unable to obtain blood samples creatinine result available from 05.10.16= 80 Ceftriaxone
only creatinine blood taken unable to bleed patient for immune response samples Ceftriaxone
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
BD NAATs from × 3 sites accidently discarded at baseline Ceftriaxone
Pharangeal culture not sent at baseline in error Ceftriaxone
There were not freezing isolates at this particular time Gentamicin
U+ E not sent for serum creatinine in error Ceftriaxone
Urethral and rectal cultures not sent in error Ceftriaxone
No throat NAAT/culture sent at visit 2 in error Ceftriaxone
lab stopped freezing isolate at this time Ceftriaxone
Visit 1 U+ E sample not labelled so result unavailable Gentamicin
Immune samples not sent at visit 2 as no kits available Ceftriaxone
Aptima combo samples not sent at visit 2 in error Ceftriaxone
VAS not completed by patient at visit 1 in error Ceftriaxone
Lab was not keeping isolates Gentamicin
U+ E not sent at visit 2 in error Gentamicin
VAS not done at visit 2 in error Gentamicin
Urethral GC culture unable to exclude GC due to lab error Gentamicin
follow-up was performed 13 post baseline thus fell before the 14 days post baseline required Ceftriaxone
U+ Es not taken. Pt IVDU and refused after immune samples taken Gentamicin
Lab was not keeping isolates Gentamicin
lab Stopped frezzing isolate at this tiem Ceftriaxone
RECTAL SAMPLING NOT SEN IN ERROR Gentamicin
Rectal testing not done at baseline in error Gentamicin
rectal sampling not done in error Ceftriaxone
VAS not completed at visit 2 in error Ceftriaxone
Clinical lab did not save Ceftriaxone
Patients clinic number not on tracking sheet so lab could not follow up result Gentamicin
lost on subculture Gentamicin
VAS not completed at visit 1 in error Gentamicin
VAS not complete Gentamicin
immune response not taken Gentamicin
creatinine not taken Gentamicin
Sample left in incubator for too long – unable to process in lab Gentamicin
v 2 ocurred day12 as patietn unable to coemanother day Gentamicin
Creatinine resutls not available due to lab error Gentamicin
Follow up: incorrectly sampled pharynx in place of rectum Ceftriaxone
Visual Analogue Scale not done at this visit Ceftriaxone
Visit 2 2 weeks post visit 1 but not scheduled. No G-TOG delegated Dr available. Seen by clinic staf Ceftriaxone
Immune study bloods not performed in error Ceftriaxone
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
Couldnt access MACRO db. Paper CRF not available some data not collected. Immune visit 2 blood ND Ceftriaxone
Culture sample was not transferred to STBRUa – lab error Ceftriaxone
No Side effects or use of NHS service info collected in error Gentamicin
No Visit 2 immune study bloods collected in error Gentamicin
baseline NAAT tests not obtained only pre-trial rectal NAAT +ve for GC. baseline culture was taken Gentamicin
Culture sample was not transferred to STBRUa – lab error Gentamicin
Throat sample not taken. Rectal sample not taken as patient did not admit to anal sex Ceftriaxone
VAS not completed in error Ceftriaxone
doxycycline prescribed in addition to azithromycin Gentamicin
Doxycycline erroneously prescribed in addition to G-TOG drug/azithromycin Gentamicin
failed to send urine sample for lab analysis Ceftriaxone
Full sampling profile not taken on baseline visit. Rectal and urethral NAAT and cultures missing Ceftriaxone
Culture sample was not transferred to STBRU.a Lab error Gentamicin
rectal and urethral NAAT/ culture not taken at baseline. PI error Gentamicin
Full sampling profile on baseline incomplete. Pharynx and urine NAAT/cultures missing. PI error Ceftriaxone
Culture sample was not transferred to STBRU.a Lab error Ceftriaxone
Full sampling profile on visit 1 incomplete. Urine and rectal NAAT/culture not taken Ceftriaxone
rectal and throat culture not taken at baseline Gentamicin
urine NAAT was missing. No results from the laboratory Gentamicin
at TOC visit throat culture but not TMA was obtained. Pt was recalled TMA taken 4 days later Gentamicin
lost to follow up. pt reattended for screen 23/1/16 but too late for study. All GC swabs negative Gentamicin
urine sample was missing from the laboratory Gentamicin
patient not keen on signing pt. 5 of consent. Discussed with [name] happy for data to be included Ceftriaxone
incomplete sampling profile. Rectal NAAT/ culture not taken Ceftriaxone
Culture sample was not transferred to STBRUa – lab error Gentamicin
lost to follow up Ceftriaxone
sampling error. rectal sample was not taken by mistake Ceftriaxone
Culture sample was not transferred to STBRUa – lab error Ceftriaxone
Culture sample was not transferred to STBRUa – lab error Gentamicin
Patient decline rectal swab to be taken as never had rectal swabs before. No history of anal sex Gentamicin
Culture sample was not transferred to STBRUa – lab error Gentamicin
Culture sample was not transferred to STBRU.a Lab error Ceftriaxone
lost to follow up Ceftriaxone
lost to follow up Gentamicin
patient declined rectal sample to be taken. no rectal contact on baseline Gentamicin
Prescribed doxcycline from [clinic name]. Has had 3 doses before coming for G-TOG follow up appt Gentamicin
lost to follow up Gentamicin
Patient withdrew consent for study Ceftriaxone
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
patient declined questionnaire and bloods at follow up visit due to time constraints Ceftriaxone
pt received doxycyline for 1 week due to rectal chlamydia positive result Ceftriaxone
Pt DNA TOC visit. emaield and siad he went to [clinic name] for tests on 17/8/16 & was all clear. No SEs Gentamicin
Blood sample taken from participant on 20-FEB-2015 and deliverd to the lab for creatinine testing. M Gentamicin
Some culture plates were incorrectly discarded in the laboratory and this subjects plate was amongst Gentamicin
rectal culture sample was not transferred to STBRU.a ISOLATE WAS NOT SAVED Gentamicin
NO CREATINE RESULT MARKED AS DONE Gentamicin
NO REPEAT VVS DONE AT FOLLOW UP Gentamicin
No result for urethral culture as marked as done but no result on server Ceftriaxone
PHARYNX POSITIVE ON RESULT BUT ISOLOTE WAS NOT SAVED BY THE LABORATORY Gentamicin
no result for creatitine marked as done but no result on server Ceftriaxone
uretral sample not done two cultures were sent for pharynx both were reported as negative Ceftriaxone
THE ISOLATE WAS NOT SAVED BY THE LAB FOROM THE CERVIX CULTURE THAT CAME BACK
POSITIVE FOR GC
Gentamicin
patient did not attend follow up Gentamicin
Blood sample too old to process Ceftriaxone
pharynx result culture not available lab had discarded sample and apologized as this was a mistake Ceftriaxone
CREATITINE BLOOD TOO OLD TO PROCESS Gentamicin
culture not obtained at visit 2 my mistake sorry Gentamicin
NO BLOOD KITS AVAILABLE FOR IMMUNE RESPONSE Ceftriaxone
patient reattended on the 3NOV 2015 as she tested too early on follow up her results came back NEG Ceftriaxone
Isolate was not saved from the cervix and sent to STBRUa Ceftriaxone
DID NOT ATTEND HIS FOLLOW UP APPOINTMENT Gentamicin
Did not attend follow up appointment Gentamicin
NO BLOOD KITS AVAILABLE SO BLOODS NOT DONE FOR IMMUNE RESPONSE Gentamicin
NO RESULT ON SERVER FOR CREATITNE BLOODS Gentamicin
culture only taken from Pharynx at this visit Gentamicin
patient attended follow up at 13 days as she could not attend aftre this date Ceftriaxone
vvs not repeated as already had a positive result now aware a n additional one should have been don Ceftriaxone
culture not repeated at follow up as all were negative sorry should have repeated Ceftriaxone
natts were not repeated at this visit as were all done 05-10-2015 al cultures were done Gentamicin
urethral sample positive but isilate was not saved by the labs and sent to mSTBTU Ceftriaxone
NO RESULT AVAIALBLE FOR UREATHRAL CULTURE AS PLATE WAS UNLABELED Ceftriaxone
creatitne blood taken but reported as too old to test Ceftriaxone
ISOLATE WAS NOT SAVED BY THE LABS AND WAS NOT SENT TO STBRUa Ceftriaxone
lost to follow up Gentamicin
INSUFFICIENT SAMPLE FOR CREATITINE PATIENT DIFFICULT TO BLEED Ceftriaxone
only pharynx sample was obtained at visit 1 Ceftriaxone
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
sample lost in transport. Urine Gentamicin
BLOODS DISPOSED AS UNBLINDED Gentamicin
PROBLEM AT FIRST VISIT WITH CULTURES NOT INCUBATED FOR THE RIGHT AMOUNT OF TIME SO
THESE WERE REPEAT
Ceftriaxone
result not available reported as plate not inoculated Ceftriaxone
rectal sample not done Ceftriaxone
did not attend follow up Gentamicin
sample reported as unlabelled so not processed creatitine creatitne sample Ceftriaxone
UREATHRAL SAMPLE ISOLATE WAS NOT SAVED AND SENT TO STBRUa Ceftriaxone
RECTAL CULTURE ISOLATE WAS NOT SAVED AND SENT TO STBRUa BY THE LABS Gentamicin
unable to obtain bloods 2 × attempts .Follow up visit 28-JAN-2016 CREATITNE AND IMMUNE
RESPONSE BLOO
Ceftriaxone
creatine kinase result given not creatitne as requested Ceftriaxone
THE ISOLATE WAS NOT SAVED BY THE LAB Ceftriaxone
BLOOD WAS TAKEN BUT NOT PROCESSED AS ARRIVED AT LAB LATE Ceftriaxone
no immune kits available Gentamicin
creatitine result not available as wasnt recieved in lab for 24 hours and too old to process Gentamicin
no culture result for cervix report states plate not innoculated Gentamicin
At visit 1 patient left department with his urine so no sample collected at this visit Gentamicin
lost to follow up Gentamicin
the pharyngeal culture isolate was not saved by the lab Ceftriaxone
DID NOT ATTEND FOLLOW UP Ceftriaxone
patient declined to have bloods done Ceftriaxone
patient declined to have bloods done Ceftriaxone
did not attend follow up Ceftriaxone
no creatitine result as patient declined bloods Gentamicin
did not attend follow up Ceftriaxone
did not attend follow up Gentamicin
blood creatitine taken but no result on server Gentamicin
did not attend follow up Gentamicin
PATIENT ATTENDED FOR TOC AT 7 DAYS THEN ATTENDED DAY AFTER THAT AND WAS RETREATED
AS HAD SEXUAL CON
Gentamicin
no creatitne result on server sample lost in transit or not processed Gentamicin
unable to obtain bloods 3 attempts became distressed Ceftriaxone
CREATITINE TOO OLD TO TEST BY THE TIME IT REACHEDCTHE LAB Ceftriaxone
NO BLOOD KITS AVAILABLE Gentamicin
NO BLOOD KITS AVAILABLE Ceftriaxone
no blood kits available Gentamicin
patient did not attend follow up Gentamicin
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
ISOLATE WAS NOT SAVED AS ORGANISM DIED ON PHARNX PLATE Gentamicin
no result for creatinine on server may have been lost in transit Gentamicin
DECLINED BLOODS AT VISIT 2 Gentamicin
VAS SCORE NOT DONE AS PATIENT DECLINED DID NOT HAVE THE INJECTION. DECLINED Gentamicin
No VAS sheet for visit 2 verbal from patient no change and documented on VAS sheet visit 1 by nurse Gentamicin
Microscopy not done in error Gentamicin
NAAT visit1 no result on system & pt notes no longer on site therefore pre randomistion input on mac Gentamicin
VAS sheet not given @visit2 pt asked by nurse re:changes and written on VAS sheet visit 1 Gentamicin
unable to clarify if doxycycline px and taken notes no longer on site no written info on system Gentamicin
Urine TMA sample lost so no result Ceftriaxone
No creatinine result – sent to lab? lost no result Ceftriaxone
VASsheet visit 2 not given to pt documented on VAS sheet visit 1 same value as per pt says Ceftriaxone
Visit 2 was done on day 13 and not after day 14 as included day of visit as day1 so visit early Ceftriaxone
VAS sheet not given @ visit2 documented on VAS sheet visit 1 not change in value as per patient Ceftriaxone
In error- incorporated pretrial blood with visit1 as complete screen so only NAAT pretrial results Ceftriaxone
Vas sheet visit 2 not given documented on vas sheet Visit1 same value as per patient stated Ceftriaxone
Vas score for visit 2 not completed in error Gentamicin
No creatinine result from visit 1. Lab error they performed hepatic screen and not renal screen Gentamicin
Vas sheet not given visit 2 written on vas sheet from visit 1 so 1 vas sheet in total Gentamicin
No creatinine result form baseline visit check with cmft labs no listed sample so ?? lost in transit Ceftriaxone
No Creatinine result sample not done in error.PI aware Gentamicin
Urethral microscopy not performed at visit 2 in error Ceftriaxone
Visual Analogue scale not completed in error Gentamicin
Retreated for GC by GUM 17/11/2015 as non compliance Ceftriaxone
Never attended for visit 2 Ceftriaxone
Creatinine not done in error so no result for this visit Ceftriaxone
Culture plates not taken from sites 5 and 2 dr decision Ceftriaxone
Naat testinfg not taken from site 2 & 5 dr decision Ceftriaxone
No NAAT for PHarynx taken at baseline. Unknown reason why as culture was obtained Ceftriaxone
Culture not taken in error Gentamicin
No follow up examination made. – patient believed to be a false pos on micro Gentamicin
No RECtal NAAT or Culture taken at follow up- patient believed to be negative Gentamicin
dr decision not to test UR culture Gentamicin
VAS scale not completed by participant at visit 2 Gentamicin
patient declined some baseline swabs -no UR culture taken Ceftriaxone
Unable to obtain visit 2 immunology bloods due to poor blood flow Ceftriaxone
source data missing for weight assume visually patient weight greater than 40 kg Ceftriaxone
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
Clinician unaware immunology samples required at follow up. Education provided Gentamicin
Patient reports no receptive anal sex therefore original assessing clinician did not take Ceftriaxone
VAS score not taken at follow up Ceftriaxone
Immunology bloods not taken at follow up Gentamicin
VAS not taken at Follow up Gentamicin
Bacterial Vaginosis at visit 1 Ceftriaxone
Creatinine blood not taken at visit 2 Ceftriaxone
Cultures not taken visit 2 – user error – education provided Ceftriaxone
VAS score not taken visit 2. Busy clinic Ceftriaxone
Participant diagnosed with bacterial vaginosis at baseline Gentamicin
Immunology bloods not taken at visit 2 Gentamicin
Duration of pain not asked of patient. User Error – education provided Gentamicin
Rectal swabs not taken at baseline- patient declined swabs Gentamicin
Rectal NAAT not taken and urine taken at drs discretion Gentamicin
Creatine blood not obtained at visit 1. The request was made but not recieved in labs Ceftriaxone
Newly trained nurse was not aware that CREATINE WAS required at visit 1 – training provided Ceftriaxone
Rectal and pharangeal swabs not taken at v1. this was a user error and a reminder was made Gentamicin
Rec and additional swabs not taken on date of visit 1 – user error and training offered Gentamicin
Rec and Ph cultures not taken at visit 2. User error and reminders were provided Ceftriaxone
PH and REC swab not taken at visit 2 in error Gentamicin
U and E blood taken at visit 1 but not recieved in labs. Local investigation taking place Ceftriaxone
Rec swabs not taken in error Gentamicin
Vas score not taken at visit two patient fainted so limited for time Ceftriaxone
disgnosis of BV Gentamicin
GRAM STAIN NOT REPEATED FOR RECTAL SLIDE POSITIVE AT BASELINE Gentamicin
NAAT sample for pharynx result not available ? lost retaken pon 6th may Gentamicin
Culture sample for phaynx result not available ?lost retaken on 6th May Gentamicin
urethral culture plate sample not taken Ceftriaxone
patient disclosed long standing chronic conditon Dr diagnosed PID Gentamicin
Pharynx naat sample not taken no Oral Sex Ceftriaxone
Pharynx culture not taken No oral sex Ceftriaxone
No Rectal Naat done ? No Anal Sex Gentamicin
No Rectal culture done ? No anal sex Gentamicin
Urethral swab not done No penetrative sex Ceftriaxone
NAAT Rectum sample not performed Ceftriaxone
CULTURE Rectum sample not performed Ceftriaxone
VISUAL ANALOGUE SCALE NOT COMPLETED Ceftriaxone
phyical exam not done in error Gentamicin
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
Pencillin allergy Gentamicin
Follow-up visual analgue scale not done in error Ceftriaxone
no rectal Naats result available for visit 1 Gentamicin
pt left clinic before clinical examination swabs and bloods taken Gentamicin
Rectal Naats and culture was not repeated at Visit 2 Gentamicin
serum creatine not done in error Gentamicin
The culture sample was not taken at visit 2 Ceftriaxone
Culture not taken at Visit 2 Ceftriaxone
Naat Testing performed as routine clinic appointment and not at V2 Ceftriaxone
Culture testing not performed at routine visit also not performed at V2 Ceftriaxone
Unable to obtain blood sampling at V2 – 3 × attempts Ceftriaxone
Rectal culture not performed at Baseline Ceftriaxone
GC culture (R) isolate not saved by laboratory Ceftriaxone
Positive result for visit 2 Ur GC culture samples reported on Lastword – sample not stored by lab Gentamicin
No creatinine result available from lab (lab error) Gentamicin
Noted after patient left that GC diagnosis over 4/52 ago. PI & G-TOG team informed immediately Ceftriaxone
Cepheid machine error – TH. Previous BD NAAT neg. Culture neg. AC NAAT sent. Will repeat at v2 for
safety
Ceftriaxone
Error result on Cepheid machine for GC Th NAAT. Returned 09-May-2016 to repeat Gentamicin
Triple site AC NAATs and cultures sent at visit 1 but local NAATs not repeated Gentamicin
Site not clear from culture samples- will repeat triple site at visit 2 for completeness Gentamicin
AC NAATs and cultures sent at visit 1 on 01-Jul-2016. Local NAATs not repeated Ceftriaxone
Creatinine result not available-?mismatched sample/labelling error Ceftriaxone
throat swab result shown as error on 22/08/16 at local lab. patient will be recalled to reswab throa Ceftriaxone
Patient didnt come for repeat throat swab after multiple attempts to contact as dated on 05/09/16 Ceftriaxone
technical error results with the machine for rectal swabs. patient will be recalled to reswab site Ceftriaxone
PRE BASELINE SYPHILIS TEST WAS NEGATIVE BUT CONFIRMED RESULTS OF 12/09/2016 CAME AS
POSITIVE
Gentamicin
Culture sample not taken from infected site at visit 2 - Oversight by nurse covering study visit Ceftriaxone
Culture sample not taken at follow-up visit. Oversight by nurse covering visit Gentamicin
No Creatinine visit 2 - porter failed to deliver sample in time for processing Gentamicin
CREATININE SAMPLE NOT PROCESSED DUE TO PORTER FAILING TO DELIVER TO LAB Gentamicin
Porter failed to deliver sample to path intime and sample was no processed Ceftriaxone
CREATININE NOT TAKEN IN ERROR Gentamicin
Copy of positive GC lab result not available at time of recruitment as tested at London clinic Gentamicin
Symptom assessment /Follow up:genital discharge negative but the symptom resolution period
unknown
Gentamicin
VISUAL ANALOGUE SCALE WAS NOT DONE ON VISIT 1 – BASELINE Gentamicin
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
PATIENT ALLERGIC TO AZITHROMYCIN Gentamicin
BV DIAGNOSED ON LOCAL SLIDE NOT SEEN Gentamicin
PATIENT DECLINED NAAT AND CULTURE SET OF SCREENING SWABS RECTAL AND PHARYNX ONCE
RANDOMISED
Gentamicin
PARTICIPANT DID NOT ATTEND HIS FOLLOW UP VISIT LOST TO FOLLOW UP AS PER PROTOCOL Ceftriaxone
LOCAL LABORATORY URINE NAAT TEST NOT DONE/BASELINE VISIT Gentamicin
PHARYNX LOCAL LABORATORY CULTURE TEST/FOLLOW UP VISIT NOT DONE Gentamicin
FOLLOW UP VISIT DONE 13 DAYS AFTER THE BASELINE VISIT BY MISTAKE Gentamicin
VISUAL ANALOGUE SCALE NOT DONE AT THE BASELINE VISIT Ceftriaxone
VISUAL ANALOGUE SCALE AT THE FOLLOW UP VISIT NOT DONE Ceftriaxone
VISUAL ANALOGUE SCALE NOT DONE Ceftriaxone
CREATININE RESULT NOT AVAILABLE AT VISIT 1 Gentamicin
NAAT AND CULTURE PHARYNGEAL TESTING NOT DONE IN THE F/U VISITNAAT POSITIVE ONLY IN
SCREENING VISIT
Ceftriaxone
Pharynx NAAT negative on visit one retested by mistake in visit 2 Gentamicin
PARTICIPANT WAS NOT ELIGIBLE Gentamicin
Blood sample for creatinine issed in error. Nurses are aware they need to take this sample for futur Gentamicin
culture of urethreal sample only taken in error. Aware need sample from all sites for next patient Gentamicin
NAAT Pharyngeal sample taken in error at baseline visit Ceftriaxone
Pharyngeal culture omitted in error at Follow up visit Ceftriaxone
Rectal NAAT sample taken in error at follow up visit. Removed from eCRF as requested Gentamicin
Visit 1 NAAT samples are missing from local IT system Ceftriaxone
Pt tested in London told +ve came here for Rx & enrolled.Later found result equivocal Gentamicin
Samples taken from rectum and pharynx for NAAT testing but no results available from lab Ceftriaxone
Rectal sample not done Ceftriaxone
Pharyngeal result not done (NAAT testing) Ceftriaxone
Baseline urethra sample not available Ceftriaxone
Blood sample not taken due to venepuncture difficulties Ceftriaxone
Additional swab not taken for AC testing. Unknown reason Ceftriaxone
No GC culture taken at Visit 1 from urethral site Gentamicin
No GC CULTURE AT VISIT 1 FROM THE THROAT Gentamicin
NO URETHRAL GC CULTURE TAKEN ON VISIT 1 Ceftriaxone
DATE ON CHEMICAL PATHOLOGY REQUEST FORM MISREAD BY LAB STAFF AND SAMPLE NOT
PROCESSED
Gentamicin
URETHRAL GC CULTURE NOT TAKEN Ceftriaxone
THROAT CULTURE NOT TAKEN BY GUM STAFF PRIOR TO RANDOMISATION Ceftriaxone
AC swab missed and not obtained at Enrolment visit Gentamicin
Throat swab for NAAT not done at visit 2. Patient came back to have the sample taken on 2 Sept 2016 Gentamicin
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TABLE 41 Protocol deviations recorded on the protocol deviation log (continued )
Details Treatment group
VAS not completed on baseline visit Gentamicin
VAS form missed during the Visit 1 Ceftriaxone
Weight not done on Visit 1 Ceftriaxone
BV, bacterial vaginosis; CK, creatine kinase; CRF, case report form; GUM, genitourinary medicine; IVDU, intravenous drug
user; PID, pelvic inflammatory disease; QEHB, Queen Elizabeth Hospital Birmingham; STBRU, Sexually Transmitted Bacteria
Reference Unit; U + E, urea and electrolytes.
a Owing to STBRU closure during the trial, swabs were analysed by PHE.
Text is taken directly from source data CRF forms with redactions made to remove staff names and clinic names.
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FIGURE 17 Distribution of genital gentamicin MIC. (a) All participants; and (b) by treatment response.
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FIGURE 18 Distribution of pharyngeal gentamicin MIC. (a) All participants; and (b) by treatment response.
Fr
eq
u
en
cy
 (
n
)
1 2 4 8
Gentamicin MIC distribution (mg/l)
0
20
40
60
(a)
Fr
eq
u
en
cy
 (
n
)
2 4
Gentamicin MIC distribution (mg/l)
(b)
0
5
10
15
20
Non-responder
Responder
FIGURE 19 Distribution of rectal gentamicin MIC. (a) All participants; and (b) by treatment response.
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FIGURE 20 Distribution of genital ceftriaxone MIC. (a) All participants; and (b) by treatment response.
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FIGURE 21 Distribution of pharyngeal ceftriaxone MIC. (a) All participants; and (b) by treatment response.
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FIGURE 22 Distribution of rectal ceftriaxone MIC. (a) All participants; and (b) by treatment response.
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FIGURE 23 Distribution of genital azithromycin MIC. (a) All participants; and (b) by treatment response.
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FIGURE 24 Distribution of pharyngeal azithromycin MIC. (a) All participants; and (b) by treatment response.
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FIGURE 25 Distribution of rectal azithromycin MIC. (a) All participants; and (b) by treatment response.
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